Genetic risk factors modulate the association between physical activity and colorectal cancer

Genetic risk factors modulate the association between physical activity and colorectal cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Genetic risk factors modulate the association between physical activity and colorectal cancer Anita R. Peoples, Mireia Obón-Santacana, Andre E. Kim, Eric S. Kawaguchi, and 70 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7350654/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Feb, 2026 Read the published version in BMC Medicine → Version 1 posted 9 You are reading this latest preprint version Abstract Background Physical activity (PA) is an established protective factor for colorectal cancer (CRC), but it is unclear if genetic variants modify this effect. To investigate this possibility, we conducted a genome-wide gene–PA interaction analysis. Methods Using logistic regression and two-step and joint tests, we analyzed interactions between common genetic variants across the genome and PA in relation to CRC risk. Self-reported PA levels were categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk) and as study- and sex-specific quartiles of activity. Results PA had an overall protective effect on CRC (OR [active vs. inactive] = 0.85; 95%CI = 0.81–0.90). The two-step GxE method identified an interaction between rs4779584, an intergenic variant near the GREM1 and SCG5 genes, and PA for CRC risk (p-interaction = 2.6×10 − 8 ). Stratification by genotype at this locus showed a significant reduction in CRC risk by 20% in active vs. inactive participants with the CC genotype (OR = 0.80; 95%CI = 0.75–0.85), but no significant PA–CRC association among CT or TT carriers. When PA was modeled as quartiles, the 1-d.f. GxE test identified that rs56906466, an intergenic variant near the KCNG1 gene, modified the association between PA and CRC (p-interaction = 3.5×10 − 8 ). Stratification at this locus showed that increase in PA (highest vs. lowest quartile) was associated with a lower CRC risk solely among TT carriers (OR = 0.77; 95%CI = 0.72–0.82). Conclusions In summary, we identified two genetic variants that modified the association between PA and CRC risk. One of them, related to GREM1 and SCG5 , suggests that the bone morphogenetic protein (BMP)-related, inflammatory, and/or insulin signaling pathways may be associated with the protective influence of PA on colorectal carcinogenesis. physical activity gene-environment interaction colorectal cancer GWAS Figures Figure 1 BACKGROUND Colorectal cancer (CRC) is a major global cause of morbidity and mortality. It is the third most commonly diagnosed cancer and second leading cause of death in the world, with more than 1.9 million incident cases and 0.9 million deaths in 2020 [1]. It is predicted that there will be 2.2 million and 3.2 million new CRC cases by 2030 [2] and 2040 [3], respectively, confirming CRC as a major continuing public health burden. The underlying etiology of CRC is multifactorial with a combination of genetic and environmental factors increasing the likelihood of developing CRC [4]. Among these risk factors, physical activity, a lifestyle factor, is an established protective factor against CRC [5–9]. Multiple observational studies and several systematic reviews have shown that regular physical activity (occupational or leisure time) is a modifiable factor associated with lower CRC risk [10–13]. In particular, the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Continuous Update Project reported lower CRC risk with increased physical activity and classified the evidence linking physical activity to lower CRC risk as ““strong” [5]. Despite the beneficial health effects of physical activity, a recent study reported that more than a quarter of all adults globally were not getting sufficient physical activity [14]. There is substantial understanding of the mechanisms underlying the protective association of physical activity with CRC risk, for example, physical activity is known to have beneficial effects on skeletal muscle mass, immune function, sleep, and mental health [7, 15–21]. Physical activity also reduces obesity (fat mass), which has a beneficial effect on CRC through a reduction in insulin resistance and inflammation, both of which have been associated with CRC development [7, 22–24]. More recently, physical activity has been linked to improved gut microbiome diversity [25]. Further, non-modifiable genetic factors may play a role between physical activity and CRC. However, only a few gene-environment (GxE) interaction studies to date have investigated the association of physical activity with CRC risk according to genetic variants [26–29], all of which were limited by small sample size or restricted to candidate genes/pathways. Understanding the genetic factors that may influence the relationship between physical activity and CRC risk can offer novel insights into potential biological mechanisms of colorectal carcinogenesis, as well as better inform efforts to promote physical activity and potentially identify individualized physical activity prescriptions. We conducted the largest genome-wide GxE analysis to date, aiming to identify novel genetic variants that may modify the protective association between self-reported physical activity and CRC risk in order to obtain insight into potential mechanisms behind this association. METHODS Study participants The study included individual level genomic and epidemiologic data from three CRC consortia: the multi-centered Colon Cancer Family Registry (CCFR), the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and the Colorectal Cancer Transdisciplinary Study (CORECT), which have been previously described [30–35]. Nested case-control sets were assembled from cohort studies. Control participants were matched on age, sex, and enrollment date/trial group, when applicable. CRC cases were defined as invasive colon or rectal tumors and were confirmed via multiple sources including electronic medical records, pathology reports, state or provincial cancer registries, and/or death certificates. For the small subset of advanced adenomas (7–8%), matched controls were polyp-free and were confirmed by sigmoidoscopy or colonoscopy at the time of adenoma diagnosis. Each study was approved by relevant ethics committees or review boards from respective institutions. All participants provided written informed consent at recruitment. Data harmonization Data were collected and centralized at the GECCO consortium coordinating center at the Fred Hutchinson Cancer Center [34]. Briefly, data harmonization consisted of a multi-step procedure, in which common data elements (CDEs) were defined a priori for data harmonization. Study questionnaires and data dictionaries were examined and, through an iterative process of communication with data contributors, elements were mapped to these CDEs. Definitions, permissible values, and standardized coding were implemented into a single database via SAS and T-SQL. Resulting data were checked for errors and outlying values within and between studies [36]. Epidemiologic and lifestyle data collection Information on demographic, lifestyle, and environmental factors as well as potential risk factors such as age at diagnosis or enrollment, sex, education level, smoking status, total energy consumption (kcal/day), and self-reported or measured weight and height were collected via in-person interviews or through structured self-administered questionnaires in each study. Total energy consumption was derived from the Food Frequency Questionnaires, with missing values imputed by study-sex-specific means. Body mass index (BMI) was calculated using the weight (kg) and height (m) of each participant. Physical activity exposure measure Information on physical activity was obtained from structured questionnaires, such as the International Physical Activity Questionnaire (IPAQ) short form [37], European Prospective Investigation into Cancer and Nutrition (EPIC) physical activity questionnaire, and Nurses' Health Study physical activity questionnaire, among others. Physical activity was estimated in metabolic equivalent tasks hours per week (MET-h/wk), which was derived for each participant, to determine the approximate average amount of time per week that the individual spent in leisure activities or all activities if leisure was not specified. Moderate activity was defined as 3.5 to 6 MET-h/wk and vigorous activities as ≥ 6 MET-h/wk [38]. Thus, at least 8.75 MET-h/wk approximately corresponds to the current physical activity guidelines of a minimum of 150 minutes (= 2.5 hours) of moderate or 75 minutes of vigorous activity per week as recommended for individuals with cancer or for cancer prevention [39–42]. Based on these guidelines and previously published literature in CRC [43–45], the participants in the present study were categorized into two groups: active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk; reference category). Because the majority of the participants were active, we also calculated study- and sex-specific quartiles for physical activity as a secondary variable, where the quartile groups were coded as 1, 2, 3, or 4, respectively. This variable was treated as continuous (change in one quartile) when assessing the association between physical activity and CRC, and as categorical (1st quartile as reference group) in the genome-wide scans. Genotyping, quality control, and imputation Detailed information on genotyping, imputation, and quality control have been described previously [30, 32]. In brief, genotyped single nucleotide polymorphisms (SNPs) were excluded based on deviation from Hardy-Weinberg Equilibrium (p < 1x10 − 4 ), low call rate (< 95–98%), discrepancies between reported and genotypic sex, and discordant calls between duplicates. Autosomal SNPs in all studies were imputed to the Haplotype Reference Consortium (HRC) r1.1 (2016) panel using the University of Michigan Imputation Server [46] and treated as dosage for data management and analyses using R package BinaryDosage [47]. Imputed common SNPs were excluded if they had low imputation quality ( R 2 7.2 million SNPs were used for the gene-environment interaction analysis, noticeably with high redundancy due to linkage disequilibrium (LD). Sample size Analyses were limited to individuals of European ancestry, based on self-reported race and clustering of principal components (PCs) with 1000 Genomes EUR superpopulations [48]. Participants were excluded based on cryptic relatedness or duplicates (prioritizing cases and/or individuals genotyped on the better platform), and genotyping/imputation errors. We also excluded studies that did not collect physical activity data. The pooled sample size for the study- and sex-specific quartile physical activity variable was 42,602 participants from 31 studies (71% prospective cohort studies). For the dichotomous active-inactive physical activity variable, with 8.75 MET-h/wk as the cutoff value, the final pooled sample size was 39,992 participants from 27 studies (74% prospective cohort studies) ( Supplementary Table 1 ). Statistical Analyses To evaluate the main effects of physical activity on CRC risk, logistic regression models were conducted for each study, with adjustment for age at diagnosis or enrollment, sex, and total energy consumption (when available). Models with genetic variables were further adjusted for the first three PCs of genetic ancestry to account for potential population substructure. The study-specific results were combined using random-effects meta-analysis methods (Hartung-Knapp) to obtain summary odds ratios (ORs) and 95% confidence intervals (CIs) [49]. The heterogeneity p-values were calculated using Cochran’s Q statistics [50], while funnel plots identified studies with outlying ORs for potential exclusion and sensitivity analyses. Additional models were fitted, stratified by study design (case-control vs. cohort), sex, and tumor site (proximal colon, distal colon, rectal). All meta-analyses were performed using the R package Meta [51]. Genome-wide interaction scans of common markers were conducted in the overall study population to maximize power. For the purposes of this study, E indicates physical activity, G indicates a particular SNP, D indicates CRC disease status, and C refers to a set of adjustment covariables. We utilized not only the traditional logistic regression test of GxE (1-degree of freedom test; 1-d.f.), but also the more powerful joint 3-d.f. test [52, 53] and two-step EDGE method [54–56]. The R package GxEScanR [57] was used to perform these analyses. For the 1-d.f. test, we examined multiplicative interactions by fitting a traditional logistic regression model including an interaction term in the form: \(\:logit\left({Pr}\left(D=1|G\right)\right)={\beta\:}_{0}+{\beta\:}_{G}G+{\beta\:}_{E}E+\:{\beta\:}_{GxE}GxE+{\beta\:}_{C}C\) , where \(\:H0:{\beta\:}_{GxE}=0\) tests potential departures from multiplicative associations of E and G on D . We also performed a joint test of association, which can improve power to detect disease susceptibility loci in a wider range of circumstances by accounting for GxE interactions, e.g., in circumstances where susceptibility loci affect only individuals with certain environmental exposure profiles [53, 58]. For this we used the 3-d.f. test of the joint null hypothesis \(\:H0={\beta\:}_{G}={\beta\:}_{GxE}={\gamma\:}_{G}=0\) , where \(\:\:{\beta\:}_{G}\:\text{a}\text{n}\text{d}{\:\beta\:}_{GxE}\) are the main and interaction effects from the logistic model above and \(\:{\gamma\:}_{G}\) represents the association between G and E in the combined case-control sample [53, 59]. We further implemented the two-step EDGE method that assesses GxE interaction tests (step 2) based on ranks of an independent filtering or ranking statistic (step 1) [56]. The two-step method can decrease the multiple testing burden and improve power to detect interaction loci [56, 59, 60], provided that steps 1 and 2 are independent. The original approach uses step 1 ranks to prioritize and partition SNPs into exponentially larger bins of fixed sizes and increasingly more stringent step- 2 significance thresholds. However, when analyzing imputed SNPs, highly correlated markers from the same loci fill the top bins, thereby diminishing statistical power. To address this issue, the original weighted hypothesis-testing framework [61] was modified to accommodate bins of varying sizes while appropriately controlling for type I error [55]. In particular, SNPs were partitioned into bins based on step 1 p-value thresholds in expectation , which were calculated using the original predetermined bin sizes (initial bin size of 5 and overall alpha = 0.05) with assumed uniform distribution of 1 million independent tests. For step 2 GxE testing, the influx of correlated markers into each bin was accounted for by correcting for the effective number of tests, which was estimated using principal component analysis (PCA) performed on bin-specific genotype correlation matrices [54, 55, 62]. This modification reduces multiple testing burden and improves statistical power, while preserving the overall type I error rate at 5%. For any SNP achieving significance at the overall type I error rate, we computed its corresponding SNP-specific p-value accounting for both steps 1 and 2 of the EDGE procedure, to allow direct comparison to the standard GWAS threshold of 5 x 10 − 8 [62]. To follow-up statistically significant interactions, we estimated stratified ORs by modeling physical activity in relation to CRC within genotypic groups and the per-allele increase in genotype in relation to CRC stratified by physical activity. We also assessed the extent of genomic inflation by creating quantile-quantile (Q-Q) plots and calculating the genomic inflation factor (lambda). Additionally, we calculated lambda 1000 , which scales the genomic inflation factor to an equivalent study of 1000 cases and 1000 controls, since as lambda scales according to the sample size [63, 64]. To explore variation in GxE effect strengths of association, we also conducted stratified analyses for novel findings by study design, sex, and tumor site. We conducted a sensitivity analysis including the interaction terms GxBMI and E(= physical activity)xBMI in the model, because BMI it is a potential confounder in the physical activity−CRC association [65]. Functional follow-up Regional plots for all statistically significant findings were generated using the command- line version (standalone) of LocusZoom v1.3 [66] to examine, in depth, the magnitudes of association, the extent of association signal due to LD, and chromosomal position of findings relative to genes in the given region. Measures of LD were estimated using study population controls. The putative functional role of these SNPs and those in LD (R 2 > 0.5) at 500 kb flanking regions were examined relative to their potential contribution to regulate gene expression by their: i) direct association with expression of nearby genes (expression quantitative trait loci (eQTLs); and ii) physical location in regions of chromatin accessibility or histone modifications (variant enhancer loci). Possible eQTL relationships were explored using: i) the Genotype-Tissue Expression (GTEx v8); and ii) the University of Barcelona and University of Virginia genotyping and RNA sequencing project (BarcUVa-Seq) dataset, which includes normal colon tissue samples from 445 healthy individuals [67]. In addition, the BarcUVa-Seq project has data on physical activity in 352 (79%) participants, which we also used to test both specific eQTLs for physical activity status (active vs. inactive; study- and sex-specific quartile variable) and interactions between SNPs and physical activity on gene expression. The BarcUVA-Seq models were adjusted for age (years), sex, sequencing batch (one to four), and tissue location (left, right, transverse, missing). The putative functional role of SNPs and those in LD (r2 > 0.2) and MAF > 0.01 at 500kb flanking regions were investigated relative to their potential contribution to regulate gene expression by their physical location in regions of chromatin accessibility or histone modifications (variant enhancer loci). We annotated only suggestive eQTLs, i.e., those having a nominal p-value < 0.05. Details of the functional- annotations analyses have been previously published [68, 69]. Briefly, we used an assay for transposase-accessible chromatin with sequencing (ATAC-seq), DNaseI Hypersensitivity (DHS)-seq, H3K27ac histone ChIP-seq, H3K4me1 histone ChIP-seq datasets of primary tissue from healthy colon and primary-tumor primary tissue samples containing active enhancer elements from Scacheri et al. [70], as well as from three CRC cell lines (SW480, HCT116, COLO205). These datasets were processed through ENCODE ATAC-seq/DNASE-seq [71] and histone ChIP-seq pipelines [72] to perform alignment and peak calling. GxE analyses for rare variants To assess the potential contribution of rare SNPs, we also performed a gene-set-based aggregate tests only for rare SNPs using the Mixed effects Score Test for Interactions (MiSTi) approach [73] as a secondary analysis, as the power for rare SNPs testing usually is low. We examined the interactions of physical activity and aggregated rare SNP sets at the gene and enhancer level using MiSTi (MiSTi R package). We used a Fisher’s combination approach under MiSTi (fMiSTi) to discover GxE interactions [73], after adjusting for age, sex, study, and the first three PCs. Because 25,000 gene regions were tested and this was a secondary analysis, interactions with p < 2x10 − 6 were considered statistically significant, while whereas those with p < 1x10 − 4 were considered suggestive. RESULTS Study population characteristics The total sample size was n = 39,992 (16,383 CRC cases and 23,609 controls), with 76% classified as active (i.e., ≥ 8.75 MET-h/wk). Detailed descriptive characteristics of the study population are presented in Table 1 . Compared to controls, CRC cases were more likely to be older, female, ever smokers, have a higher BMI and total energy consumption, and have a lower education level (each p < 0.001). Descriptive characteristics of the study population for the secondary physical activity variable assessed as study- and sex-specific quartiles are provided in Supplementary Table 2. Table 1 Descriptive characteristics of all study participants by colorectal cancer case-control status with available physical activity data. Characteristics Cases (N = 16,383) Controls (N = 23,609) P -value Age (median imputed) a Mean (SD) 65.0 (± 9.4) 63.4 (± 8.3) < 0.001 Sex Female 8,677 (53%) 12,005 (51%) < 0.001 Male 7,706 (47%) 11,604 (49%) Total energy consumption (kcal/day; mean imputed) b,c Mean (SD) 1,967 (± 713) 1,910 (± 680) < 0.001 BMI (kg/m 2 ) c Mean (SD) 27.2 (± 4.7) 26.9 (± 4.5) < 0.001 Family history of colorectal cancer c No 10,430 (64%) 12,945 (55%) 0.06 Yes 2,295 (14%) 2,685 (11%) Education level (highest completed) c Less than High School 3,070 (19%) 3,488 (15%) < 0.001 High School/GED 3,366 (21%) 3,161 (13%) Some College 3,476 (21%) 5,783 (24%) College/Graduate School 5,601 (34%) 8,488 (36%) Ever smoker c No 7,050 (43%) 11,479 (49%) < 0.001 Yes 9,086 (55%) 11,862 (50%) NOTE: Data might not add to 100% because of rounding. Abbreviations: SD, standard deviation; BMI, Body-Mass-Index; GED, General Educational Development Test. Physical activity categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk; reference category) dichotomous variable. a Age was assessed at diagnosis or enrollment. b Calculations exclude individuals with missing total energy intake information. c Missing values not shown. P -values < 0.05 are statistically significant. Physical activity and CRC risk We observed that being active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk) was associated with a 15% risk reduction in CRC in the overall meta-analysis (OR = 0.85; 95% CI = 0.81−0.90; Supplementary Fig. 1A; Supplementary Table 3 ). Sensitivity analyses showed even greater risk reduction for case-control studies (OR = 0.75; 95% CI = 0.66−0.85) compared to cohort-based studies (OR = 0.88; 95% CI = 0.83−0.93). No evidence for heterogeneity was observed across all studies ( P het =0.64; I 2 = 0%;) or among case-control ( P het =0.36; I 2 = 9%) or cohort-based studies ( P het =0.91; I 2 = 0%). Further, analysis stratified by sex showed a risk reduction in both men (OR = 0.83; 95% CI = 0.76−0.90; P het =0.56; I 2 = 0%) and women (OR = 0.87; 95% CI = 0.81−0.94; P het =0.86; I 2 = 0%) when comparing active vs. inactive participants. For tumor site, the strongest inverse associations were observed for distal colon (OR = 0.77, 95% CI = 0.71−0.84; P het =0.64; I 2 = 0%) and proximal colon (OR = 0.84, 95% CI = 0.81−0.90; P het =0.46; I 2 = 0%), but not for rectal cancer (OR = 0.94, 95% CI = 0.85−1.04; P het =0.27; I 2 = 15%) comparing active vs. inactive participants. For physical activity measured as study- and sex-specific quartiles (treated as a continuous variable), we observed similar risk reductions for the overall meta-analysis as well as for stratified analysis by sex ( Supplementary Fig. 1B; Supplementary Table 4 ). In dose-response (per-quartile) analyses, inverse associations were also observed for rectal cancer (per quartile OR = 0.95; 95% CI = 0.92–0.98; P het <0.001; I 2 = 54%) as well as for distal and proximal colon, with some inter-study heterogeneity observed for case-control studies ( P het <0.001; I 2 = 74%). As we found statistically significant associations between physical activity and CRC for the overall population without significant evidence for heterogeneity, we conducted genome-wide GxE testing in the overall study population to maximize power. Genome-wide physical activity-interaction scans for CRC risk The quantile-quantile (Q-Q) plot for the traditional gene-physical activity interactions for CRC risk using 1-d.f. analysis did not show p-value inflation for either primary and or secondary physical activity variables ( Supplementary Fig. 2 ). Table 2 summarizes the statistically significant gene-physical activity interactions identified. Using the two-step EDGE method and the dichotomous physical activity variable (active vs. inactive), we identified statistically significant interactions for 5 SNPs, all of them in LD, on chromosome 15q13.3 located in the intergenic region between Gremlin 1 ( GREM1 ) and Secretogranin V ( SCG5 ) genes.[74] Among these SNPs with statistically significant interactions, we report only on the interaction of SNP rs4779584 with physical activity in this study (two-step p-value = 2.6x10 − 8 ; Table 2 ), as this SNP was supported by prior evidence on the association with CRC as main effect (per T allele OR: active = 1.20; 95% CI = 1.10–1.20 vs. inactive = 1.00; 95% CI = 0.93−1.10; Table 3 ).[75] This result was robust in a sensitivity analysis that further accounted for BMI and interactions with BMI, as well as age, sex, study type, total energy consumption, and the first three PCs of genetic ancestry. Specifically, these additional adjustments caused less than a 2% change in the GxPA interaction estimates. Analysis stratified by rs4779584 genotype showed that participants who were physically active vs. inactive had 20% lower CRC risk among those who were carriers of CC (OR = 0.80; 95% CI = 0.75−0.85; p = 1.6x10 − 11 ), while this risk reduction was diminished among those carrying the CT (OR = 0.92; 95% CI = 0.84−1.00) and TT (OR = 1.30; 95% CI = 1.00-1.70;) genotypes (Fig. 1 ; Table 3 ). We observed similar interaction effects when analyses were stratified for study type, sex, or tumor site ( Supplementary Table 5 ). Table 2 Results of genome-wide interaction analyses with physical activity for colorectal cancer risk. Physical Activity Variable SNP Chr BP Position Locus Closest Gene Reference Allele Alternate Allele Alternate Allele frequency Type Statistical Method P -value GxE b Active / Inactive a rs4779584 15 32994756 15q13.3 GREM1 and SCG5 C T 0.20 Intergenic variant Two-step EDGE 2.6x10 − 8 Quartiles c rs56906466 20 49693755 20q4.5 KCNG1 T C 0.06 Intron 1-d.f. test 3.5x10 − 8 Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; BP Position, base pair position based on NCBI Build 37; 1-d.f., 1-degree of freedom. a Physical activity categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk; reference category). b P -value corresponds to the interaction between genetic variants (G) and physical activity (E) on risk of colorectal cancer in the combined case-control population based on the indicated statistical method. c Physical activity assessed as study- and sex-specific quartiles. P -values that are statistically significant are indicated in bold text. Notes: Directly genotyped SNPs were coded as 0, 1, or 2 copies of the count allele. Imputed SNPs were coded as expected gene dosage. Multiplicative interaction terms were modelled as the product of PA and each SNP of interest. Table 3 Associations between physical activity for colorectal cancer risk stratified by genotypes of SNPs of interest. SNP Physical Activity Homozygous non-carriers Heterozygous Homozygous carries of the alternate/minor allele Per alternative allele within strata of Physical Activity categories N (Ca/Co) OR (95% CI) P -value N (Ca/Co) OR (95% CI) P -value N (Ca/Co) OR (95% CI) P -value OR (95% CI) P -value CC CT TT rs4779584 Inactive a 2,537/3,642 1.00 (Ref.) − 1,304/1,806 1.00 (0.95–1.10) 0.40 137/228 0.87 (0.69–1.10) 0.23 1.00 (0.93–1.10) 0.98 Active a 7,701/11,960 0.80 (0.75–0.85) 1.6x10 − 11 4,155/5,372 0.95 (0.89-1.00) 0.19 549/601 1.10 (0.99–1.30) 0.08 1.20 (1.10–1.20) 2.0x10 − 15 Active vs. inactive (by genotype) − 0.80 (0.75–0.85) 1.6x10 − 11 − 0.92 (0.84-1.00) 0.05 − 1.30 (1.00-1.70) 0.04 TT TC CC rs56906466 Q1 b 4,168/5,290 1.00 (Ref.) − 443/715 0.77 (0.67–0.87) 8.0x10 − 5 20/19 1.10 (0.56–2.10) 0.81 0.77 (0.68–0.88) 1.4x10 − 4 Q2 b 4,085/5,745 0.91 (0.85–0.96) 0.002 481/710 0.87 (0.76–0.99) 0.03 13/25 0.61 (0.3–1.20) 0.16 0.93 (0.82–1.10) 0.28 Q3 b 3,792/5,896 0.81 (0.76–0.86) 6.8x10 − 12 469/669 0.87 (0.77-1.00) 0.047 21/26 1.00 (0.56–1.90) 0.96 1.10 (0.99–1.30) 0.08 Q4 b 3,342/5,564 0.77 (0.72–0.82) 1.1x10 − 16 442/637 0.94 (0.82–1.10) 0.35 17/13 1.90 (0.91–4.20) 0.09 1.30 (1.10–1.50) 5.7x10 − 4 Q2 vs. Q1 (by genotype) a − 0.91 (0.85–0.96) 0.002 − 1.10 (0.95–1.30) 0.16 − 0.56 (0.21–1.50) 0.23 Q3 vs. Q1 (by genotype) a − 0.81 (0.76–0.86) 6.8x10 − 12 − 1.10 (0.96–1.40) 0.14 − 0.93 (0.38–2.30) 0.88 Q4 vs. Q1 (by genotype) a − 0.77 (0.72–0.82) 1.1x10 − 16 − 1.20 (1.00-1.50) 0.03 − 1.80 (0.65–4.90) 0.26 Abbreviations: SNP, single nucleotide polymorphism; PA, physical activity; N, number; Ca/Co, case/control; OR, odds ratio; 95% CI, 95% confidence interval. Case/control counts were calculated by imputed genotype probabilities. a Physical activity categorized as active (≥ 8.75 MET-h/wk) vs. inactive (< 8.75 MET-h/wk; reference category) b Physical activity, assessed as study- and sex-specific quartiles. P -values that are statistically significant are indicated in bold text. The analysis of physical activity assessed as study- and sex-specific quartiles revealed an interaction with one SNP (rs56906466) on chromosome 20q4.5 located near the Potassium Voltage-Gated Channel Modifier Subfamily G Member 1 ( KCNG1 ) gene, using the traditional 1-d.f. test (GxE p-value = 3.5x10 − 8 ; Table 2 ; Supplementary Fig. 3B ). This result was still consistent in a sensitivity analysis that also considered BMI and interactions with BMI along with age, sex, study type, total energy consumption, and the first three PCs of genetic ancestry. As in the previous sensitivity analysis, these adjustments resulted in less than a 2% variation in the GxPA interaction estimates. Analysis stratified by rs56906466 genotype showed statistically significantly lower CRC risk with increases in physical activity, especially when comparing the highest quartile (Q4) to the lowest quartile (Q1), among those who were carriers of TT (OR = 0.77; 95% CI = 0.72−0.82; p = 1.1x10 − 16 ). The corresponding inverse associations were not observed for those with TC (Q4 vs. Q1: OR = 1.20; 95% CI = 1.00−1.50; p = 0.03) and CC (Q4 vs. Q1: OR = 1.80; 95% CI = 0.65−4.90; p = 0.26) genotypes (Table 3 ). Similar interactions were observed when analyses were stratified by study type, sex, or tumor site ( Supplementary Table 5 ). No other statistically significant interactions were observed (data not shown). Additionally, the GxE analyses for rare variants did not identify any statistically significant interactions. There was also no significant LD-based correlation between rs4779584 and rs56906466 (correlation coefficient, r 2 = 0.001). Functional follow-up Functional annotation analyses around rs4779584 and rs56906466 showed enhanced activities. The SNP rs4779584 and correlated SNPs showed peaks in both normal (i.e., ATAC-seq, H3K4me1) and colon tumor samples (i.e., tumor DHS, tumor H3K27ac) as well as in cancer cell lines (i.e., H3K27ac, H3K4me1). The SNP rs56906466, although not correlated with other SNPs, was identified as a variant enhancer for tumor DHS and cell line DHS ( Supplementary Figs. 4–5 ). Two independent sources of eQTLs analyses were used to expand on the regulatory roles of SNPs rs4779584 and rs56906466. The SNP rs4779584 was observed to be an eQTL in the GTEx v8 compendium as it modified the expression of GREM1 in liver and pancreas, SCG5 in liver, and RP11- 758N13.1 in brain, cultured fibroblast, liver, and pancreas tissues. We did not observe any statistically significant eQTL findings for SNP rs56906466. In relation to the BarcUVa-Seq dataset, which provides colon-specific eQTLs, the SNP in the 15q13.3 region did not modify the expression of FNM1, GREM1, SCG5 , or other genes in the region ( Supplementary Fig. 4) . Likewise, the models tested in this dataset on the interaction with physical activity measured in the subjects did not reach statistical significance. The same approach was used to assess whether the SNP rs56906466 and the interaction term had eQTL effects on gene expression, but no statistically significant results were observed. DISCUSSION To our knowledge, this is the largest genome-wide study conducted to date to investigate the interactions between variants across the genome and self-reported, harmonized physical activity data. Consistent with previous studies and the WCRF, we observed a statistically significant 15% risk reduction in CRC due to physical activity, similar in magnitude to that previously observed [5, 10–13]. Our analyses identified two novel, statistically significant GxE interactions for physical activity – SNPs rs4779584 and rs56906466 significantly modified the association between physical activity and CRC risk. The SNP rs4779584, located in the 15q33.3 region, lies between the GREM1 and SCG5 genes and has been previously found to contribute to CRC susceptibility [31, 74, 76–79]. Carrying the T allele in rs4779584 has been reported to be associated with an increased CRC risk of 1.26 (95% CI = 1.19−1.34) as compared to the C allele [80]. In our study, we found that physical activity was significantly associated with a lower risk of CRC only among those with the C allele. GREM1 encodes gremlin 1, which is a signaling protein involved in several pathways relevant to CRC, including the transforming growth factor-β (TGF-β) pathway which has been implicated in tumor invasion and metastasis [81]. GREM1 is also a proangiogenic factor, suggesting a possible role in cancer development when upregulated [82]. Additionally, Gremlin 1 is an insulin antagonist with elevated levels in type 2 diabetes [83], and has been linked to bone morphogenetic proteins (BMPs) signaling imbalance, which accelerates tumor cell proliferation [84], and is associated with inflammatory processes independently of BMPs [85, 86], SCG5 encodes secretogranin V (also named 7B2 protein or SGNE1), an essential neuroendocrine signaling molecule that plays a role in cellular proliferation [87, 88]. Although SCG5 is associated with polyposis syndromes which is linked with CRC risk [89], its direct role in CRC is not as well characterized as compared to GREM1 ’s role in CRC [90]. Further, some studies have also reported a role of SCG5 in BMI modulation [91, 92]. The identified interactions suggest that the CRC risk reduction due to physical activity may be related to one or several more of these above-mentioned pathways. There are only a small number of GWAS studies that have identified genetic loci associated with physical activity [93, 94], with one preclinical study suggesting that exercise training epigenetically reprograms GREM1 expression [95]. However, to our knowledge, no prior studies have reported an interaction between rs4779584 and physical activity on CRC risk. The epidemiologic evidence indicating the beneficial effect of physical activity on CRC risk is extensive, and several biological mechanisms have been identified or proposed, including in some intervention studies, such as physical activity’s effect on immune system, systemic inflammatory markers, energy regulation, hormones levels, insulin resistance, and gut microbial composition [7, 96–98]. Related to our findings, a randomized trial conducted in obese patients who followed different resistance training protocols observed significant reductions in plasma gremlin 1 and C-reactive protein levels compared to a control group [99]. Additionally, myokines (i.e., cytokines), such as myostatin (member of the TGF-β family) or interleukin-6, are secreted by the skeletal muscle in response to intensity training [100, 101]. The effect of regular exercise on SCG5 , the other gene close to the SNP rs4779584 that showed interactions with physical activity on CRC risk, has been investigated in experimental studies using animal models. However, the results were inconclusive, with one study reported non-significantly decreased SCG5 expression, while the other study reported significantly increased expression levels [102, 103]. Future studies are warranted to describe the plausible biological mechanism by which SNP rs4779584 interacts with physical activity and modifies CRC risk, but on the basis of our findings, genetic markers in this region showed enhanced activity in both normal and tumor samples suggesting a potential regulatory role on transcription of adjacent genes. Consistent with this, we observed that SNP rs4779584 modified the expression of GREM1 and SCG5 in pancreas and liver, but not in colon tissue. We also discovered a new locus rs56906466 located near KCNG1 that has not been previously associated with CRC, physical activity, or its interaction with physical activity on CRC risk. This gene encodes a member of the large gene family that instructs the building of potassium channels and is abundantly expressed in skeletal muscle. KCNG1 has been related to insulin secretion, muscle contraction, and neurotransmitter release regulation, among others [104]; however, its functions are not fully understood. Our findings showed that rs56906466 had statistically significant interactions with physical activity in modifying CRC risk. Furthermore, functional-annotations analyses demonstrated that some of the genetic variants interacting with physical activity were located in enhancers and were linked to differential gene expression. However, additional targeted studies will be necessary to further investigate the joint effects of these genes with physical activity on CRC risk. There is increasing evidence that gene-physical activity interactions (including being physically active or inactive) have an effect on several health-related outcomes such as blood pressure, hypertension, BMI, and insulin metabolism [105]. However, few studies have evaluated the gene-physical activity interaction on CRC risk, and all previous studies followed a candidate-gene approach and included only a limited number of SNPs [26–29]. Two studies evaluated the mediating effects of physical activity on CRC risk via alterations in polymorphisms in the insulin-like growth factor-1 ( IGF-1 ) gene, since physical activity is known to modulate IGF-1 serum levels, and observed statistically significant interactions [26, 106]. Khoury-Shakour et al . focused their analysis on the polymorphism rs2665802 at intron 4 of the growth hormone 1 ( GH1 ) gene and observed that the minor allele A was associated with lower risk of CRC among inactive participants [26]. A recent study assessed the interaction between physical activity and CRC risk based on a polymorphism (rs647161) in the paired-like homeodomain 1 ( PITX1 ) gene in a Korean population, and reported a higher risk of CRC among participants who exercised less and carried the minor allele [27]. PITX1 is considered a tumor suppressor gene [107], and is known to influence the expression of GH1 , and is related to IGF-1 [108]. Song et al . assessed interactions between physical activity and 31 SNPs (including rs4779584) on CRC risk among 703 CRC cases and 1,406 healthy controls [28]. However, they observed statistically significant interactions only with rs4444235––with increased CRC risk among C carriers who exercised regularly––but not for rs4779584, which may be due to the small sample size. However, none of the above findings could be replicated in the present study (data not shown). Additionally, we observed no LD-based correlation between rs4779584 and rs4444235 ( r 2 = 0.004). Given the smaller sample size and candidate gene approach in the study by Song et al ., it is possible that these are chance findings. A main strength of our study was a large, well-characterized study population, the largest ever to have examined gene-physical activity interactions. The use of several complementary statistical approaches was also a strength of this study as it allowed detection of specific loci within GREM1 and SCG5 and near KCNG1 genes. However, our findings may not be generalizable outside of European-descent populations as the participants in this study were limited to those with European descent and were far more active than the US general population. The consortium is actively striving to overcome this limitation by expanding our research to encompass other racial and ethnic groups, as well as by harmonizing epidemiological data, which will enable us to expand our future GxE analyses. Additionally, this study included self-report measures of physical activity which are prone to recall and response biases, but these are likely to attenuate ‘true’ associations with disease risk [109]. Lastly, our sample size did not allow us to identify genes, whose rare variants may interact with physical activity and contribute to CRC risk in the aggregate test. Additional functional studies are needed to verify the role of the identified SNPs interacting with physical activity for CRC risk. CONCLUSIONS In conclusion, we identified two novel genetic loci that interact with physical activity to influence CRC risk. Potential mechanisms behind the interaction of rs4779584 and physical activity in CRC risk may be linked in part to the BMP-related, inflammation pathways, and/or insulin signaling in response to physical activity. However, SNP rs56906466 that is near a potassium channel gene, has not been previously described in relation to physical activity or CRC, and additional investigations are required to elucidate the potential mechanisms through which it may be involved in colorectal carcinogenesis, especially in individuals who are not physically active. Declarations Authors contributions All authors participated in the revisions to this paper, the interpretation of the results, and approved the final paper. Conceptualization : A.R.P, M.O-S., W.J.G.,U.P., V.M., A.E.K., E.S.K., L.M., Y.L. Data curation : A.E.K., E.S.K., C.Q., F.M-N., J.M., Y.L. Formal analysis: Q.F, A.E.K, E.S.K., C.Q, F.M-N., J.M., Y.L. Methodology : A.R.P, M.O-S, W.J.G.,U.P., V.M. A.E.K, E.S.K, C.Q, F.M-N., J.M., Y.L. Writing—original draft : A.R.P, M.O-S., W.J.G., U.P., V.M., A.E.K., E.S.K., J.M, Y.L. Writing—Review and editing : All. Supervision : U.P., W.J.G., V.M. Acknowledgements CCFR : The Colon CFR graciously thanks the generous contributions of their study participants, dedication of study staff, and the financial support from the U.S. National Cancer Institute, without which this important registry would not exist. The authors would like to thank the study participants and staff of the Seattle Colon Cancer Family Registry and the Hormones and Colon Cancer study (CORE Studies). CPS-II : The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention’s National Program of Cancer Registries and cancer registries supported by the National Cancer Institute’s Surveillance Epidemiology and End Results Program. The study protocol was approved by the institutional review boards of Emory University, and those of participating registries as required. The authors assume full responsibility for all analyses and interpretation of results. The views expressed here are those of the authors and do not necessarily represent the American Cancer Society or the American Cancer Society – Cancer Action Network. DACHS : We thank all participants and cooperating clinicians, and everyone who provided excellent technical assistance. EPIC : Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. Harvard cohorts (HPFS, NHS) : The study protocol was approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Central registries may also be supported by state agencies, universities, and cancer centers. Participating central cancer registries include the following: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kentucky, Louisiana, Massachusetts, Maine, Maryland, Michigan, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Seattle SEER Registry, South Carolina, Tennessee, Texas, Utah, Virginia, West Virginia, Wyoming. WHI : The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: https://s3-us-west-2.amazonaws.com/www-whi-org/wp-content/uploads/WHI-Investigator-Long-List.pdf Funding Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) : National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088, R01 CA059045, U01 CA164930, R21 CA191312, R01201407, R01CA488857, R01CA273198, R01CA244588). Genotyping/Sequencing services were provided by the Center for Inherited Disease Research (CIDR) contract number HHSN268201700006I and HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. Statistical methodology and software development at USC funded by P01CA196569. Colon Cancer Family Registry (CCFR) : CCFR (www.coloncfr.org) is supported in part by funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The CCFR Set-1 (Illumina 1M/1M-Duo) and Set-2 (Illumina Omni1-Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143247 (to GC). The CCFR Set-3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488 (to SBG). The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported by NIH award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research (CIDR), which is funded by the NIH to the Johns Hopkins University, contract number HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201-043 from the Ontario Research Fund (to BWZ), award 112746 from the Canadian Institutes of Health Research (to TJH), through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society (to SG), and through generous support from the Ontario Ministry of Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to PAN). The content of this manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government, any cancer registry, or the CCFR. COLO2&3 : National Institutes of Health (R01 CA060987). Colorectal Cancer Transdisciplinary (CORECT) Study : The CORECT Study was supported by the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health and Human Services (grant numbers U19 CA148107, R01 CA81488, P30 CA014089, R01 CA197350; P01 CA196569; R01 CA201407) and National Institutes of Environmental Health Sciences, National Institutes of Health (grant number T32 ES013678). CPS-II : The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. The study protocol was approved by the institutional review boards of Emory University, and those of participating registries as required. DACHS : This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1 and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A and 01ER1505B). DALS : National Institutes of Health (R01 CA48998 to M. L. Slattery). EDRN : This work is funded and supported by the NCI, EDRN Grant (U01 CA 84968-06). EPIC : The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam- Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). Harvard cohorts (HPFS, NHS) : HPFS is supported by the National Institutes of Health (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35 CA197735), and NHS by the National Institutes of Health (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, and R35 CA197735). Hawaii Adenoma Study : NCI grants R01 CA072520. LCCS : The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and Cancer Research UK Programme Award (C588/A19167). MEC : National Institutes of Health (R37 CA054281, P01 CA033619, and R01 CA063464). NCCCS I & II : We acknowledge funding support for this project from the National Institutes of Health, R01 CA66635 and P30 DK034987. NFCCR : This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, U.S. Department of Health and Human Serivces (U01 CA74783); and National Cancer Institute of Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and Génome Québec Innovation Centre, Montréal, Canada, for genotyping the Sequenom panel in the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society Research Institute. Swedish Mammography Cohort and Cohort of Swedish Men : This work is supported by the Swedish Research Council /Infrastructure grant, the Swedish Cancer Foundation, and the Karolinska Institute´s Distinguished Professor Award to Alicja Wolk. UK Biobank : This research has been conducted using the UK Biobank Resource under Application Number 8614. VITAL : National Institutes of Health (K05 CA154337). WHI : The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001,75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005. Data availability The dataset used in the current study may be available from the corresponding author on reasonable request for researchers who meet the criteria for access to confidential data. Ethics approval and consent to participate The study was conducted in accordance with the principles of the Declaration of Helsinki, each contributing study was approved by an Institutional Review Board or relevant research committee. For CPS-II, written informed consent was received from participants to obtain medical records. At the time of each mailed survey, participants were informed that their identifying information would be used to link with cancer registries and death indexes. For the other studies, all study participants provided informed consent. Consent for publication Not applicable. Competing interests Dr. Ulrich has as HCI Cancer Center Director oversight over research funded by several pharmaceutical companies but has not received funding directly herself. Dr. Peters was a consultant with AbbVie and her husband is holding individual stocks for the following companies: BioNTech SE – ADR, Amazon, CureVac BV, NanoString Technologies, Google/Alphabet Inc Class C, NVIDIA Corp, Microsoft Corp. Other authors declare that they have no conflict of interest. Disclaimer Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. References Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries . CA Cancer J Clin 2021, 71 (3):209-249. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global patterns and trends in colorectal cancer incidence and mortality . Gut 2017, 66 (4):683-691. Xi Y, Xu P: Global colorectal cancer burden in 2020 and projections to 2040 . Transl Oncol 2021, 14 (10):101174. Sawicki T, Ruszkowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybylowicz KE: A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis . Cancers (Basel) 2021, 13 (9). World Cancer Research Fund/American Institute for Cancer Research. Continous Update Project Expert Report 2018. Diet, nutrition, physical activity and colorectal cancer. Available at dietandcancerreport.org . In . Van Blarigan EL, Meyerhardt JA: Role of physical activity and diet after colorectal cancer diagnosis . J Clin Oncol 2015, 33 (16):1825-1834. Ulrich CM, Himbert C, Holowatyj AN, Hursting SD: Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms . Nat Rev Gastroenterol Hepatol 2018, 15 (11):683-698. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K: Body Fatness and Cancer--Viewpoint of the IARC Working Group . N Engl J Med 2016, 375 (8):794-798. Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, Kazmi N, Robinson TM, Albanes D, Aleksandrova K et al : Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis . Nat Commun 2020, 11 (1):597. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML et al : Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013 . BMJ 2016, 354 :i3857. Matthews CE, Moore SC, Arem H, Cook MB, Trabert B, Hakansson N, Larsson SC, Wolk A, Gapstur SM, Lynch BM et al : Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk . J Clin Oncol 2020, 38 (7):686-697. McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A et al : Physical Activity in Cancer Prevention and Survival: A Systematic Review . Med Sci Sports Exerc 2019, 51 (6):1252-1261. Morris JS, Bradbury KE, Cross AJ, Gunter MJ, Murphy N: Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank . Br J Cancer 2018, 118 (6):920-929. Guthold R, Stevens GA, Riley LM, Bull FC: Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants . Lancet Glob Health 2018, 6 (10):e1077-e1086. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS: Sarcopenia . J Lab Clin Med 2001, 137 (4):231-243. Kruijsen-Jaarsma M, Revesz D, Bierings MB, Buffart LM, Takken T: Effects of exercise on immune function in patients with cancer: a systematic review . Exerc Immunol Rev 2013, 19 :120-143. Sitlinger A, Brander DM, Bartlett DB: Impact of exercise on the immune system and outcomes in hematologic malignancies . Blood Adv 2020, 4 (8):1801-1811. Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS: Exercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012, 21 (1):3-19. Brown JC, Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker E, LaCroix JM, Ferrer RA, Johnson BT: The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis . PLoS One 2012, 7 (1):e30955. Kredlow MA, Capozzoli MC, Hearon BA, Calkins AW, Otto MW: The effects of physical activity on sleep: a meta-analytic review . J Behav Med 2015, 38 (3):427-449. Takemura N, Cheung DST, Smith R, Deng W, Ho KY, Lin J, Kwok JYY, Lam TC, Lin CC: Effectiveness of aerobic exercise and mind-body exercise in cancer patients with poor sleep quality: A systematic review and meta-analysis of randomized controlled trials . Sleep Med Rev 2020, 53 :101334. Murphy N, Cross AJ, Abubakar M, Jenab M, Aleksandrova K, Boutron-Ruault MC, Dossus L, Racine A, Kuhn T, Katzke VA et al : A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) . PLoS Med 2016, 13 (4):e1001988. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski RT et al : Adipokines linking obesity with colorectal cancer risk in postmenopausal women . Cancer Res 2012, 72 (12):3029-3037. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y: C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis . Cancer Causes Control 2014, 25 (10):1397-1405. Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA et al : Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients . Am J Cancer Res 2022, 12 (10):4789-4801. Khoury-Shakour S, Gruber SB, Lejbkowicz F, Rennert HS, Raskin L, Pinchev M, Rennert G: Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008, 17 (12):3314-3318. Gunathilake MN, Lee J, Cho YA, Oh JH, Chang HJ, Sohn DK, Shin A, Kim J: Interaction between physical activity, PITX1 rs647161 genetic polymorphism and colorectal cancer risk in a Korean population: a case-control study . Oncotarget 2018, 9 (7):7590-7603. Song N, Lee J, Cho S, Kim J, Oh JH, Shin A: Evaluation of gene-environment interactions for colorectal cancer susceptibility loci using case-only and case-control designs . BMC Cancer 2019, 19 (1):1231. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD: Insulin-like growth factor polymorphisms and colorectal cancer risk . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005, 14 (5):1204-1211. Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK et al : Discovery of common and rare genetic risk variants for colorectal cancer . Nat Genet 2019, 51 (1):76-87. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K et al : Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis . Gastroenterology 2013, 144 (4):799-807 e724. Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H et al : Novel Common Genetic Susceptibility Loci for Colorectal Cancer . J Natl Cancer Inst 2019, 111 (2):146-157. Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, Hsu L, Huang SC, Fischer CP, Harju JF et al : Genome-wide association study of colorectal cancer identifies six new susceptibility loci . Nat Commun 2015, 6 :7138. Hutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, Nan H, Lemire M, Rangrej J, Figueiredo JC et al : Characterization of gene-environment interactions for colorectal cancer susceptibility loci . Cancer Res 2012, 72 (8):2036-2044. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K et al : Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis . Gastroenterology 2013, 144 (4):799-807.e724. Rolland B, Reid S, Stelling D, Warnick G, Thornquist M, Feng Z, Potter JD: Toward Rigorous Data Harmonization in Cancer Epidemiology Research: One Approach . Am J Epidemiol 2015, 182 (12):1033-1038. Littman AJ, White E, Kristal AR, Patterson RE, Satia-Abouta J, Potter JD: Assessment of a one-page questionnaire on long-term recreational physical activity . Epidemiology 2004, 15 (1):105-113. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C: Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association . Med Sci Sports Exerc 2007, 39 (8):1435-1445. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, George SM, Olson RD: The Physical Activity Guidelines for Americans . Jama 2018, 320 (19):2020-2028. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A et al : American College of Sports Medicine roundtable on exercise guidelines for cancer survivors . Med Sci Sports Exerc 2010, 42 (7):1409-1426. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T et al : American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity . CA Cancer J Clin 2012, 62 (1):30-67. WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA et al : Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance) . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2018, 27 (6):696-703. Hardikar S, Newcomb PA, Campbell PT, Win AK, Lindor NM, Buchanan DD, Makar KW, Jenkins MA, Potter JD, Phipps AI: Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015, 24 (7):1130-1137. Kuiper JG, Phipps AI, Neuhouser ML, Chlebowski RT, Thomson CA, Irwin ML, Lane DS, Wactawski-Wende J, Hou L, Jackson RD et al : Recreational physical activity, body mass index, and survival in women with colorectal cancer . Cancer Causes Control 2012, 23 (12):1939-1948. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy S, McGue M et al : Next-generation genotype imputation service and methods . Nat Genet 2016, 48 (10):1284-1287. Morrison J: https://cran.r-project.org/package=BinaryDosage . 2020. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: An integrated map of genetic variation from 1,092 human genomes . Nature 2012, 491 (7422):56-65. IntHout J, Ioannidis JP, Borm GF: The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method . BMC Med Res Methodol 2014, 14 :25. Cochran WG: The combination of estimates from different experiments . 1954, 10 :101-129. Guido Schwarzer JRC, Gerta Rücker.: Meta-Analysis with R . Switzerland: Springer, Cham; 2015. Dai JY, Logsdon BA, Huang Y, Hsu L, Reiner AP, Prentice RL, Kooperberg C: Simultaneously testing for marginal genetic association and gene-environment interaction . Am J Epidemiol 2012, 176 (2):164-173. Gauderman WJ, Kim A, Conti DV, Morrison J, Thomas DC, Vora H, Lewinger JP: A Unified Model for the Analysis of Gene-Environment Interaction . American journal of epidemiology 2019, 188 (4):760-767. Gao X, Starmer J, Martin ER: A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms . Genet Epidemiol 2008, 32 (4):361-369. Kawaguchi ES, Kim AE, Lewinger JP, Gauderman WJ: Improved two-step testing of genome-wide gene-environment interactions . bioRxiv 2022:2022.2006.2014.496154. Gauderman WJ, Zhang P, Morrison JL, Lewinger JP: Finding novel genes by testing G × E interactions in a genome-wide association study . Genet Epidemiol 2013, 37 (6):603-613. Morrison JL, Gauderman WJ (2020). GxEScanR: Run GWAS/GWEIS Scans Using Binary Dosage Files. R package version 2.0.2. https://CRAN.R-project.org/package=GxEScanR . Kraft P, Yen YC, Stram DO, Morrison J, Gauderman WJ: Exploiting gene-environment interaction to detect genetic associations . Hum Hered 2007, 63 (2):111-119. Murcray CE, Lewinger JP, Gauderman WJ: Gene-environment interaction in genome-wide association studies . Am J Epidemiol 2009, 169 (2):219-226. Kooperberg C, Leblanc M: Increasing the power of identifying gene x gene interactions in genome-wide association studies . Genetic epidemiology 2008, 32 (3):255-263. Ionita-Laza I, McQueen MB, Laird NM, Lange C: Genomewide weighted hypothesis testing in family-based association studies, with an application to a 100K scan . American journal of human genetics 2007, 81 (3):607-614. Lewinger JP, Kawaguchi ES, Gauderman WJ: A note on p-value multiple-testing adjustment for two-step genome-wide gene-environment interactions scans . medRxiv 2023. de Bakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, Voight BF: Practical aspects of imputation-driven meta-analysis of genome-wide association studies . Hum Mol Genet 2008, 17 (R2):R122-128. Devlin B, Roeder K: Genomic control for association studies . Biometrics 1999, 55 (4):997-1004. Sun M, Bjorge T, Teleka S, Engeland A, Wennberg P, Haggstrom C, Stocks T: Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study . Int J Cancer 2022, 151 (6):859-868. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ: LocusZoom: regional visualization of genome-wide association scan results . Bioinformatics 2010, 26 (18):2336-2337. Diez-Obrero V, Dampier CH, Moratalla-Navarro F, Devall M, Plummer SJ, Diez-Villanueva A, Peters U, Bien S, Huyghe JR, Kundaje A et al : Genetic Effects on Transcriptome Profiles in Colon Epithelium Provide Functional Insights for Genetic Risk Loci . Cell Mol Gastroenterol Hepatol 2021, 12 (1):181-197. Jordahl KM, Shcherbina A, Kim AE, Su YR, Lin Y, Wang J, Qu C, Albanes D, Arndt V, Baurley JW et al : Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region . Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2022, 31 (5):1077-1089. Tian Y, Kim AE, Bien SA, Lin Y, Qu C, Harrison T, Carreras-Torres R, Diez-Obrero V, Dimou N, Drew DA et al : Genome-Wide Interaction Analysis of Genetic Variants with Menopausal Hormone Therapy for Colorectal Cancer Risk . J Natl Cancer Inst 2022. Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L et al : Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome . Nat Commun 2017, 8 :14400. Lee J, Jolanki O, Kim D, Strattan JS, Kundaje A, Nordström K, Shcherbina A: ENCODE-DCC/atac-seq-pipeline: v1.9.1 . 2020. Lee J, Strattan JS, Shcherbina A, Kagda M, Maurizio PL: ENCODE-DCC/chip-seq-pipeline2: v1.6.1 . 2020. Su YR, Di CZ, Hsu L, Genetics, Epidemiology of Colorectal Cancer C: A unified powerful set-based test for sequencing data analysis of GxE interactions . Biostatistics 2017, 18 (1):119-131. Tu L, Yan B, Peng Z: Common genetic variants (rs4779584 and rs10318) at 15q13.3 contributes to colorectal adenoma and colorectal cancer susceptibility: evidence based on 22 studies . Mol Genet Genomics 2015, 290 (3):901-912. Yang H, Gao Y, Feng T, Jin TB, Kang LL, Chen C: Meta-analysis of the rs4779584 polymorphism and colorectal cancer risk . PLoS One 2014, 9 (2):e89736. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, Edlund CK, Haile RW, Gallinger S, Zanke BW et al : Meta-analysis of new genome-wide association studies of colorectal cancer risk . Hum Genet 2012, 131 (2):217-234. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, Lloyd A, Kinnersley B, Gorman M, Tenesa A et al : Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis . Hum Mol Genet 2014, 23 (17):4729-4737. Tanskanen T, van den Berg L, Valimaki N, Aavikko M, Ness-Jensen E, Hveem K, Wettergren Y, Bexe Lindskog E, Tonisson N, Metspalu A et al : Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci . Int J Cancer 2018, 142 (3):540-546. Rakshit S, Bhaskar LVKS: An Intergenic Variant rs4779584 Between SCG5 and GREM1 Contributes to the Increased Risk of Colorectal Cancer: A Meta-Analysis . In: Novel therapeutic approaches for gastrointestinal malignancies Diagnostics and Therapeutic Advances in GI Malignancies. edn. Edited by Nagaraju GP, Peela S. Singapore: Springer; 2020: 159-169. Jaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittman A, Kemp Z et al : Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk . Nat Genet 2008, 40 (1):26-28. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression . Nat Genet 2001, 29 (2):117-129. Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F et al : Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor . Blood 2007, 109 (5):1834-1840. Hedjazifar S, Khatib Shahidi R, Hammarstedt A, Bonnet L, Church C, Boucher J, Bluher M, Smith U: The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH . Diabetes 2020, 69 (3):331-341. Kobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, Lida T, Ando R, Suzuki N, Lannagan TRM et al : The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis . Gastroenterology 2021, 160 (4):1224-1239 e1230. Ren J, Smid M, Iaria J, Salvatori DCF, van Dam H, Zhu HJ, Martens JWM, Ten Dijke P: Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression . Breast Cancer Res 2019, 21 (1):109. Corsini M, Moroni E, Ravelli C, Andres G, Grillo E, Ali IH, Brazil DP, Presta M, Mitola S: Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin . Arterioscler Thromb Vasc Biol 2014, 34 (1):136-145. Seidah NG, Chretien M: Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides . Brain Res 1999, 848 (1-2):45-62. Mbikay M, Seidah NG, Chretien M: Neuroendocrine secretory protein 7B2: structure, expression and functions . Biochem J 2001, 357 (Pt 2):329-342. Ziai J, Matloff E, Choi J, Kombo N, Materin M, Bale AE: Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: counselling and management recommendations . Genet Res (Camb) 2016, 98 :e5. Yusuf I, Pardamean B, Baurley JW, Budiarto A, Miskad UA, Lusikooy RE, Arsyad A, Irwan A, Mathew G, Suriapranata I et al : Genetic risk factors for colorectal cancer in multiethnic Indonesians . Sci Rep 2021, 11 (1):9988. Jo Y, Yeo MK, Dao T, Kwon J, Yi HS, Ryu D: Machine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia . Front Oncol 2022, 12 :942774. Farber CR, Chitwood J, Lee SN, Verdugo RA, Islas-Trejo A, Rincon G, Lindberg I, Medrano JF: Overexpression of Scg5 increases enzymatic activity of PCSK2 and is inversely correlated with body weight in congenic mice . BMC Genet 2008, 9 :34. Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, Alexander GE, Chen Z, Going SB: Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE . Int J Obes (Lond) 2018, 42 (6):1161-1176. Doherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, Lindgren CM: GWAS identifies 14 loci for device-measured physical activity and sleep duration . Nat Commun 2018, 9 (1):5257. Fabre O, Giordani L, Parisi A, Pattamaprapanont P, Ahwazi D, Brun C, Chakroun I, Taleb A, Blais A, Andersen E et al : GREM1 is epigenetically reprogrammed in muscle cells after exercise training and controls myogenesis and metabolism . bioRxiv 2020:2020.2002.2020.956300. Jurdana M: Physical activity and cancer risk. Actual knowledge and possible biological mechanisms . Radiol Oncol 2021, 55 (1):7-17. Wang T, Zhang Y, Taaffe DR, Kim JS, Luo H, Yang L, Fairman CM, Qiao Y, Newton RU, Galvao DA: Protective effects of physical activity in colon cancer and underlying mechanisms: A review of epidemiological and biological evidence . Crit Rev Oncol Hematol 2022, 170 :103578. Dziewiecka H, Buttar HS, Kasperska A, Ostapiuk-Karolczuk J, Domagalska M, Cichon J, Skarpanska-Stejnborn A: Physical activity induced alterations of gut microbiota in humans: a systematic review . BMC Sports Sci Med Rehabil 2022, 14 (1):122. Saeidi A, Seifi-Ski-Shahr F, Soltani M, Daraei A, Shirvani H, Laher I, Hackney AC, Johnson KE, Basati G, Zouhal H: Resistance training, gremlin 1 and macrophage migration inhibitory factor in obese men: a randomised trial . Arch Physiol Biochem 2020:1-9. Ataeinosrat A, Saeidi A, Abednatanzi H, Rahmani H, Daloii AA, Pashaei Z, Hojati V, Basati G, Mossayebi A, Laher I et al : Intensity Dependent Effects of Interval Resistance Training on Myokines and Cardiovascular Risk Factors in Males With Obesity . Front Endocrinol (Lausanne) 2022, 13 :895512. Pourteymour S, Eckardt K, Holen T, Langleite T, Lee S, Jensen J, Birkeland KI, Drevon CA, Hjorth M: Global mRNA sequencing of human skeletal muscle: Search for novel exercise-regulated myokines . Mol Metab 2017, 6 (4):352-365. Saran U, Guarino M, Rodriguez S, Simillion C, Montani M, Foti M, Humar B, St-Pierre MV, Dufour JF: Anti-tumoral effects of exercise on hepatocellular carcinoma growth . Hepatol Commun 2018, 2 (5):607-620. Endo Y, Zhang Y, Olumi S, Karvar M, Argawal S, Neppl RL, Sinha I: Exercise-induced gene expression changes in skeletal muscle of old mice . Genomics 2021, 113 (5):2965-2976. Entrez Gene: KCNG1 potassium voltage-gated channel, subfamily G, member 1. Available at https://www.ncbi.nlm.nih.gov/gene/3755 . In . Bray MS, Hagberg JM, Perusse L, Rankinen T, Roth SM, Wolfarth B, Bouchard C: The human gene map for performance and health-related fitness phenotypes: the 2006-2007 update . Med Sci Sports Exerc 2009, 41 (1):35-73. Wong HL, Koh WP, Probst-Hensch NM, Van den Berg D, Yu MC, Ingles SA: Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach . Gut 2008, 57 (8):1090-1096. Ke J, Lou J, Chen X, Li J, Liu C, Gong Y, Yang Y, Zhu Y, Zhang Y, Gong J: Identification of a Potential Regulatory Variant for Colorectal Cancer Risk Mapping to Chromosome 5q31.1: A Post-GWAS Study . PLoS One 2015, 10 (9):e0138478. Liu DX, Lobie PE: Transcriptional activation of p53 by Pitx1 . Cell Death Differ 2007, 14 (11):1893-1907. Prince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M: A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review . Int J Behav Nutr Phys Act 2008, 5 :56. Additional Declarations Competing interest reported. Dr. Ulrich has as HCI Cancer Center Director oversight over research funded by several pharmaceutical companies but has not received funding directly herself. Dr. Peters was a consultant with AbbVie and her husband is holding individual stocks for the following companies: BioNTech SE – ADR, Amazon, CureVac BV, NanoString Technologies, Google/Alphabet Inc Class C, NVIDIA Corp, Microsoft Corp. Other authors declare that they have no conflict of interest. Supplementary Files SupplementaryTable1GxEPAv6FINAL.xlsx SUPPLEMENTARYTABLESANDFIGURES.docx Cite Share Download PDF Status: Published Journal Publication published 05 Feb, 2026 Read the published version in BMC Medicine → Version 1 posted Editorial decision: Revision requested 12 Nov, 2025 Reviews received at journal 12 Nov, 2025 Reviewers agreed at journal 10 Nov, 2025 Reviews received at journal 29 Oct, 2025 Reviewers agreed at journal 19 Oct, 2025 Reviewers invited by journal 22 Aug, 2025 Editor assigned by journal 12 Aug, 2025 Submission checks completed at journal 12 Aug, 2025 First submitted to journal 11 Aug, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7350654","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":508046857,"identity":"0554c596-0524-4dc7-aa8e-070ab87da295","order_by":0,"name":"Anita R. Peoples","email":"","orcid":"","institution":"American Cancer Society","correspondingAuthor":false,"prefix":"","firstName":"Anita","middleName":"R.","lastName":"Peoples","suffix":""},{"id":508046858,"identity":"8b73ec77-82a5-4fe6-beaa-25aba9cc4aa2","order_by":1,"name":"Mireia Obón-Santacana","email":"","orcid":"","institution":"Catalan Institute of Oncology (ICO), L’Hospitalet del Llobregat","correspondingAuthor":false,"prefix":"","firstName":"Mireia","middleName":"","lastName":"Obón-Santacana","suffix":""},{"id":508046859,"identity":"e258d66d-2a25-48fa-9b48-394b2035699e","order_by":2,"name":"Andre E. Kim","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Andre","middleName":"E.","lastName":"Kim","suffix":""},{"id":508046860,"identity":"a6510053-e39c-45ab-97cf-b1820a1a234a","order_by":3,"name":"Eric S. Kawaguchi","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Eric","middleName":"S.","lastName":"Kawaguchi","suffix":""},{"id":508046861,"identity":"a2ea65ca-64b2-426d-8782-2ac91a51b912","order_by":4,"name":"Yubo Fu","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Yubo","middleName":"","lastName":"Fu","suffix":""},{"id":508046862,"identity":"5e87ebc9-a534-4f73-8e75-426f723b9379","order_by":5,"name":"Conghui Qu","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Conghui","middleName":"","lastName":"Qu","suffix":""},{"id":508046863,"identity":"6c2edeee-512e-4bce-83b2-bb0dc2616ebc","order_by":6,"name":"Ferran Moratalla-Navarro","email":"","orcid":"","institution":"Catalan Institute of Oncology (ICO), L’Hospitalet del Llobregat","correspondingAuthor":false,"prefix":"","firstName":"Ferran","middleName":"","lastName":"Moratalla-Navarro","suffix":""},{"id":508046864,"identity":"cac854fa-e5a4-4ff1-8459-4fdaeaf4c66a","order_by":7,"name":"John Morrison","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"John","middleName":"","lastName":"Morrison","suffix":""},{"id":508046865,"identity":"c2787774-de70-406f-a89f-fa67f16ff139","order_by":8,"name":"Yi Lin","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Lin","suffix":""},{"id":508046866,"identity":"c100c368-8902-492b-b522-36540d77f967","order_by":9,"name":"Volker Arndt","email":"","orcid":"","institution":"German Cancer Research Center (DKFZ)","correspondingAuthor":false,"prefix":"","firstName":"Volker","middleName":"","lastName":"Arndt","suffix":""},{"id":508046867,"identity":"a2619c30-868d-45ec-b809-d45ce2974442","order_by":10,"name":"Sonja I. Berndt","email":"","orcid":"","institution":"National Cancer Institute, National Institutes of Health","correspondingAuthor":false,"prefix":"","firstName":"Sonja","middleName":"I.","lastName":"Berndt","suffix":""},{"id":508046868,"identity":"9a683def-6a9b-435b-a548-911976887569","order_by":11,"name":"Stephanie A Bien","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Stephanie","middleName":"A","lastName":"Bien","suffix":""},{"id":508046869,"identity":"1dc96a74-91e6-4d4e-8b00-faf64cded540","order_by":12,"name":"D. Timothy Bishop","email":"","orcid":"","institution":"University of Leeds","correspondingAuthor":false,"prefix":"","firstName":"D.","middleName":"Timothy","lastName":"Bishop","suffix":""},{"id":508046870,"identity":"c87fde3c-5792-42f4-a3f3-7dd81345c30c","order_by":13,"name":"Emmanouil Bouras","email":"","orcid":"","institution":"University of Ioannina School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Emmanouil","middleName":"","lastName":"Bouras","suffix":""},{"id":508046871,"identity":"2fcd8d5d-d180-4af8-bf1d-84d1715d000c","order_by":14,"name":"Hermann Brenner","email":"","orcid":"","institution":"German Cancer Research Center (DKFZ)","correspondingAuthor":false,"prefix":"","firstName":"Hermann","middleName":"","lastName":"Brenner","suffix":""},{"id":508046876,"identity":"fd766b3f-b79b-4df6-b4ec-09dc0c3c5764","order_by":15,"name":"Daniel D. Buchanan","email":"","orcid":"","institution":"The University of Melbourne","correspondingAuthor":false,"prefix":"","firstName":"Daniel","middleName":"D.","lastName":"Buchanan","suffix":""},{"id":508046877,"identity":"a3aaa86e-5761-4848-8576-b86a124ac410","order_by":16,"name":"Peter T. Campbell","email":"","orcid":"","institution":"Albert Einstein College of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Peter","middleName":"T.","lastName":"Campbell","suffix":""},{"id":508046878,"identity":"eba1cf40-e89f-4079-9974-a19da3d5c7dd","order_by":17,"name":"Andrew T. Chan","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"T.","lastName":"Chan","suffix":""},{"id":508046879,"identity":"d3dc1cec-f3e7-4a8e-b11f-dd7302b7a149","order_by":18,"name":"Jenny Chang-Claude","email":"","orcid":"","institution":"German Cancer Research Center (DKFZ)","correspondingAuthor":false,"prefix":"","firstName":"Jenny","middleName":"","lastName":"Chang-Claude","suffix":""},{"id":508046880,"identity":"70236a96-e716-42af-8563-7911e28e8e66","order_by":19,"name":"David V. Conti","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"V.","lastName":"Conti","suffix":""},{"id":508046881,"identity":"c3d2c4b8-f46b-4686-a2c6-dc94ab549ad3","order_by":20,"name":"Douglas AC. Corley","email":"","orcid":"","institution":"Kaiser Permanente Northern California","correspondingAuthor":false,"prefix":"","firstName":"Douglas","middleName":"AC.","lastName":"Corley","suffix":""},{"id":508046882,"identity":"290bff57-4c3b-4498-8f9a-319392d86e24","order_by":21,"name":"Matthew A. Devall","email":"","orcid":"","institution":"University of Virginia","correspondingAuthor":false,"prefix":"","firstName":"Matthew","middleName":"A.","lastName":"Devall","suffix":""},{"id":508046883,"identity":"89b520a1-d0b7-41d3-ab13-1220c46a91e8","order_by":22,"name":"Niki Dimou","email":"","orcid":"","institution":"International Agency for Research on Cancer, World Health Organization","correspondingAuthor":false,"prefix":"","firstName":"Niki","middleName":"","lastName":"Dimou","suffix":""},{"id":508046884,"identity":"eeb42314-d716-4a7f-9af1-b993575cafde","order_by":23,"name":"David A. Drew","email":"","orcid":"","institution":"Massachusetts General Hospital, Harvard Medical School","correspondingAuthor":false,"prefix":"","firstName":"David","middleName":"A.","lastName":"Drew","suffix":""},{"id":508046885,"identity":"131b8038-9e83-4e8d-ac3f-28de1f7a889a","order_by":24,"name":"Stephen B. Gruber","email":"","orcid":"","institution":"City of Hope National Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Stephen","middleName":"B.","lastName":"Gruber","suffix":""},{"id":508046886,"identity":"23e3ecb2-1978-4d9c-9ae6-829db1fbca6d","order_by":25,"name":"Marc J. Gunter","email":"","orcid":"","institution":"International Agency for Research on Cancer, World Health Organization","correspondingAuthor":false,"prefix":"","firstName":"Marc","middleName":"J.","lastName":"Gunter","suffix":""},{"id":508046887,"identity":"9a235654-3503-46e8-aec9-a9999ebf0dac","order_by":26,"name":"Sophia Harlid","email":"","orcid":"","institution":"Umeå University","correspondingAuthor":false,"prefix":"","firstName":"Sophia","middleName":"","lastName":"Harlid","suffix":""},{"id":508046888,"identity":"d766e775-0c82-43f0-bdea-b964213adfe6","order_by":27,"name":"Tabitha A. Harrison","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Tabitha","middleName":"A.","lastName":"Harrison","suffix":""},{"id":508046889,"identity":"d0648413-84f5-4e7e-a2fe-af4bde81b5f7","order_by":28,"name":"Michael Hoffmeister","email":"","orcid":"","institution":"German Cancer Research Center (DKFZ)","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Hoffmeister","suffix":""},{"id":508046890,"identity":"f0752597-e35a-487b-957f-65d7592e78b7","order_by":29,"name":"Li Hsu","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Hsu","suffix":""},{"id":508046891,"identity":"4acd6375-4466-4993-af12-a14a22240b73","order_by":30,"name":"Jeroen R. Huyghe","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Jeroen","middleName":"R.","lastName":"Huyghe","suffix":""},{"id":508046892,"identity":"e2929d27-5399-47fe-9106-f996e1ab3f49","order_by":31,"name":"Temitope O. Keku","email":"","orcid":"","institution":"University of North Carolina","correspondingAuthor":false,"prefix":"","firstName":"Temitope","middleName":"O.","lastName":"Keku","suffix":""},{"id":508046893,"identity":"e256ee5b-ae4b-42e9-a11b-373fc2aa7724","order_by":32,"name":"Anshul Kundaje","email":"","orcid":"","institution":"Stanford University","correspondingAuthor":false,"prefix":"","firstName":"Anshul","middleName":"","lastName":"Kundaje","suffix":""},{"id":508046894,"identity":"a821f383-1192-4bf7-a55c-fc8fd360f28b","order_by":33,"name":"Juan Pablo Lewinger","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"Pablo","lastName":"Lewinger","suffix":""},{"id":508046895,"identity":"b9298b7e-60e4-4654-9c1e-774aae862853","order_by":34,"name":"Li Li","email":"","orcid":"","institution":"University of Virginia","correspondingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Li","suffix":""},{"id":508046896,"identity":"8a3bc396-b1e5-4ce8-9e77-6ae8066f5a53","order_by":35,"name":"Brigid M. Lynch","email":"","orcid":"","institution":"Cancer Council Victoria","correspondingAuthor":false,"prefix":"","firstName":"Brigid","middleName":"M.","lastName":"Lynch","suffix":""},{"id":508046897,"identity":"0aa4ced0-ae9b-4bf1-ac9d-09bc57be65cc","order_by":36,"name":"Loic Le Marchand","email":"","orcid":"","institution":"University of Hawaii Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Loic","middleName":"Le","lastName":"Marchand","suffix":""},{"id":508046898,"identity":"bfab5a73-9e09-428f-8f19-81f389bc85dd","order_by":37,"name":"Vicente Martín","email":"","orcid":"","institution":"Universidad de León","correspondingAuthor":false,"prefix":"","firstName":"Vicente","middleName":"","lastName":"Martín","suffix":""},{"id":508046899,"identity":"6e05d97e-0ce2-48b6-91d3-51e25a0fe7e3","order_by":38,"name":"Neil Murphy","email":"","orcid":"","institution":"International Agency for Research on Cancer, World Health Organization","correspondingAuthor":false,"prefix":"","firstName":"Neil","middleName":"","lastName":"Murphy","suffix":""},{"id":508046900,"identity":"ec8aeace-e1cd-4d39-8d85-3accd2cc011b","order_by":39,"name":"Christina C. Newton","email":"","orcid":"","institution":"American Cancer Society","correspondingAuthor":false,"prefix":"","firstName":"Christina","middleName":"C.","lastName":"Newton","suffix":""},{"id":508046901,"identity":"86c4d68b-c695-4c0b-b9c0-78a073f8ea61","order_by":40,"name":"Shuji Ogino","email":"","orcid":"","institution":"Broad Institute of MIT and Harvard","correspondingAuthor":false,"prefix":"","firstName":"Shuji","middleName":"","lastName":"Ogino","suffix":""},{"id":508046902,"identity":"f8a8aca0-4a92-4189-a9ec-a8aee822dd82","order_by":41,"name":"Sheetal Hardikar","email":"","orcid":"","institution":"Huntsman Cancer Institute","correspondingAuthor":false,"prefix":"","firstName":"Sheetal","middleName":"","lastName":"Hardikar","suffix":""},{"id":508046905,"identity":"e5884c95-001f-4102-a7ac-33737157a6ee","order_by":42,"name":"Jennifer Ose","email":"","orcid":"","institution":"University of Applied Sciences and Arts","correspondingAuthor":false,"prefix":"","firstName":"Jennifer","middleName":"","lastName":"Ose","suffix":""},{"id":508046907,"identity":"c8e9e846-13ad-4b74-92b2-1fde716f0990","order_by":43,"name":"Rish K. Pai","email":"","orcid":"","institution":"Mayo Clinic Arizona","correspondingAuthor":false,"prefix":"","firstName":"Rish","middleName":"K.","lastName":"Pai","suffix":""},{"id":508046909,"identity":"86ddace1-0c04-47ec-a1db-72a03b514391","order_by":44,"name":"Julie R. Palmer","email":"","orcid":"","institution":"Slone Epidemiology Center at Boston University","correspondingAuthor":false,"prefix":"","firstName":"Julie","middleName":"R.","lastName":"Palmer","suffix":""},{"id":508046911,"identity":"f38c599e-0462-4171-896a-de0d35db6648","order_by":45,"name":"Nikos Papadimitriou","email":"","orcid":"","institution":"International Agency for Research on Cancer, World Health Organization","correspondingAuthor":false,"prefix":"","firstName":"Nikos","middleName":"","lastName":"Papadimitriou","suffix":""},{"id":508046913,"identity":"ab3e6904-dbb1-4695-a51a-c7969865ad3c","order_by":46,"name":"Bens Pardamean","email":"","orcid":"","institution":"Binus University","correspondingAuthor":false,"prefix":"","firstName":"Bens","middleName":"","lastName":"Pardamean","suffix":""},{"id":508046915,"identity":"6ed0c24d-b4bb-482c-8a5d-0de6e8351e63","order_by":47,"name":"Andrew J. Pellatt","email":"","orcid":"","institution":"University of Texas MD Anderson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Andrew","middleName":"J.","lastName":"Pellatt","suffix":""},{"id":508046916,"identity":"597e5f27-1b4b-43ad-9898-ca2c97269f54","order_by":48,"name":"Mila Pinchev","email":"","orcid":"","institution":"Lady Davis Carmel Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Mila","middleName":"","lastName":"Pinchev","suffix":""},{"id":508046918,"identity":"d5b45a18-718a-4cbf-9e72-07eb1b0ae343","order_by":49,"name":"Elizabeth A. Platz","email":"","orcid":"","institution":"Johns Hopkins Bloomberg School of Public Health","correspondingAuthor":false,"prefix":"","firstName":"Elizabeth","middleName":"A.","lastName":"Platz","suffix":""},{"id":508046921,"identity":"a2c117fd-906e-4e37-a4cc-a85bd7c0c77c","order_by":50,"name":"John D. Potter","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"John","middleName":"D.","lastName":"Potter","suffix":""},{"id":508046922,"identity":"56a49bd8-dd29-4e07-8409-f14c1c8a143d","order_by":51,"name":"Gad Rennert","email":"","orcid":"","institution":"Lady Davis Carmel Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Gad","middleName":"","lastName":"Rennert","suffix":""},{"id":508046923,"identity":"23138005-3357-4b97-9a73-801239a5eaaa","order_by":52,"name":"Edward A. Ruiz-Narvaez","email":"","orcid":"","institution":"University of Michigan School of Public Health","correspondingAuthor":false,"prefix":"","firstName":"Edward","middleName":"A.","lastName":"Ruiz-Narvaez","suffix":""},{"id":508046924,"identity":"b78edb37-5046-4da8-a960-354794df8dbd","order_by":53,"name":"Lori C. Sakoda","email":"","orcid":"","institution":"Kaiser Permanente","correspondingAuthor":false,"prefix":"","firstName":"Lori","middleName":"C.","lastName":"Sakoda","suffix":""},{"id":508046925,"identity":"985d0793-b68a-4bb2-98fa-1509ef83c73b","order_by":54,"name":"Robert E. Schoen","email":"","orcid":"","institution":"University of Pittsburgh Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Robert","middleName":"E.","lastName":"Schoen","suffix":""},{"id":508046926,"identity":"4c440c8c-e2f1-4421-a74e-2eb04c4f7b36","order_by":55,"name":"Anna Shcherbina","email":"","orcid":"","institution":"Stanford University","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"","lastName":"Shcherbina","suffix":""},{"id":508046927,"identity":"455dfb9f-ad25-4020-9612-7be0dbc8b19b","order_by":56,"name":"Mariana C. Stern","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Mariana","middleName":"C.","lastName":"Stern","suffix":""},{"id":508046928,"identity":"cd82d09c-1626-440a-b590-1b4b9aa5b476","order_by":57,"name":"Yu-Ru Su","email":"","orcid":"","institution":"Kaiser Permanente San Francisco Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Yu-Ru","middleName":"","lastName":"Su","suffix":""},{"id":508046929,"identity":"726a7e27-d60c-40de-8c11-b5acbd327d17","order_by":58,"name":"Claire E. Thomas","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Claire","middleName":"E.","lastName":"Thomas","suffix":""},{"id":508046930,"identity":"5d2052dd-dc2c-4327-8ce4-4de5ab7af4eb","order_by":59,"name":"Yu Tian","email":"","orcid":"","institution":"German Cancer Research Center (DKFZ)","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Tian","suffix":""},{"id":508046931,"identity":"cd2c56db-4f10-4bca-a2aa-85b4fdba803e","order_by":60,"name":"Konstantinos K. Tsilidis","email":"","orcid":"","institution":"University of Ioannina School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Konstantinos","middleName":"K.","lastName":"Tsilidis","suffix":""},{"id":508046932,"identity":"14622ac5-d62d-4ecf-80d0-a7988351a468","order_by":61,"name":"Caroline Y. Um","email":"","orcid":"","institution":"American Cancer Society","correspondingAuthor":false,"prefix":"","firstName":"Caroline","middleName":"Y.","lastName":"Um","suffix":""},{"id":508046933,"identity":"c0c3d8c0-f08c-4621-9dff-abb622b56ac4","order_by":62,"name":"Franzel J. B. van Duijnhoven","email":"","orcid":"","institution":"Wageningen University \u0026 Research","correspondingAuthor":false,"prefix":"","firstName":"Franzel","middleName":"J. B. van","lastName":"Duijnhoven","suffix":""},{"id":508046934,"identity":"14eae9e3-31c4-4176-8a11-2b568d19029f","order_by":63,"name":"Bethany van Guelpen","email":"","orcid":"","institution":"Umeå University","correspondingAuthor":false,"prefix":"","firstName":"Bethany","middleName":"van","lastName":"Guelpen","suffix":""},{"id":508046935,"identity":"cb452dcd-cfa2-4a3f-9b63-e7ce07f763c1","order_by":64,"name":"Kala Visvanathan","email":"","orcid":"","institution":"Johns Hopkins Bloomberg School of Public Health","correspondingAuthor":false,"prefix":"","firstName":"Kala","middleName":"","lastName":"Visvanathan","suffix":""},{"id":508046936,"identity":"a1012ca6-2352-4a62-8ba0-0864e4757b0f","order_by":65,"name":"Jun Wang","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Jun","middleName":"","lastName":"Wang","suffix":""},{"id":508046937,"identity":"565fc1d1-2473-4dfe-bbb5-889a7b3cb2fd","order_by":66,"name":"Emily White","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Emily","middleName":"","lastName":"White","suffix":""},{"id":508046938,"identity":"7d0665ad-d7cd-4dec-a301-60c881635507","order_by":67,"name":"Alicja Wolk","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Alicja","middleName":"","lastName":"Wolk","suffix":""},{"id":508046939,"identity":"69796240-ed8f-4883-b27d-2d37b4af38e1","order_by":68,"name":"Michael O. Woods","email":"","orcid":"","institution":"Memorial University of Newfoundland, St. John's","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"O.","lastName":"Woods","suffix":""},{"id":508046940,"identity":"4a76abcd-7353-4f4e-80f4-8a00516f852a","order_by":69,"name":"Anna H. Wu","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"H.","lastName":"Wu","suffix":""},{"id":508046941,"identity":"525e7b53-9170-4b64-b6b1-731a0a0a1dcb","order_by":70,"name":"Cornelia M. Ulrich","email":"","orcid":"","institution":"Huntsman Cancer Institute","correspondingAuthor":false,"prefix":"","firstName":"Cornelia","middleName":"M.","lastName":"Ulrich","suffix":""},{"id":508046942,"identity":"30e76a91-10bd-49bc-935d-f7716ba58e88","order_by":71,"name":"Ulrike Peters","email":"","orcid":"","institution":"Fred Hutchinson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Ulrike","middleName":"","lastName":"Peters","suffix":""},{"id":508046943,"identity":"d07be294-cb21-4906-a55e-845102da969e","order_by":72,"name":"W. James Gauderman","email":"","orcid":"","institution":"University of Southern California","correspondingAuthor":false,"prefix":"","firstName":"W.","middleName":"James","lastName":"Gauderman","suffix":""},{"id":508046944,"identity":"104923a3-369d-418d-a0b6-d69c3c717930","order_by":73,"name":"Victor Moreno","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA90lEQVRIiWNgGAWjYDADfmYILcPAwNhAnBbJZgjNA9MiQVCLwQG4FgjAqcXgAHfi44qKO3LGx5kfPi6oseHh51/c+IFxh00dbi28mw3PnHlmbHaYzdh4xrE0HskZD5slGM+k4bRFsoF3m2Rj2+HEbYd52KR5Gw7zGNw42CDB2HaYgJZ/hxM3NyO0NP9gbPuPUws/A0hLw+HEDcwwLecb24C2HMCthRnol4Zjh40lQH7hAfuFsc0isS1ZsgGHFjb23o0PG2oOy/H3H374mKfGRo6f//jjGx/b7Phx2cLAjCEikcDAkIBTPXa3HiBN/SgYBaNgFAx7AACLOFApCO6IrQAAAABJRU5ErkJggg==","orcid":"","institution":"Catalan Institute of Oncology (ICO), L’Hospitalet del Llobregat","correspondingAuthor":true,"prefix":"","firstName":"Victor","middleName":"","lastName":"Moreno","suffix":""}],"badges":[],"createdAt":"2025-08-12 02:53:21","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7350654/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7350654/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12916-026-04675-5","type":"published","date":"2026-02-05T15:59:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":90382065,"identity":"f29d235d-a49d-4588-bd63-06f04da81adc","added_by":"auto","created_at":"2025-09-02 06:51:19","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":81131,"visible":true,"origin":"","legend":"\u003cp\u003eAssociation between physical activity and colorectal cancer risk stratified by genotype of SNP rs4779584. Physical activity is categorized as active (≥8.75 MET-h/wk) vs. inactive (\u0026lt;8.75 MET-h/wk; reference category).\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-7350654/v1/99793183070a970f04f01120.png"},{"id":102235205,"identity":"4a197cd2-1ba8-4855-bccb-64ce1e47e2ce","added_by":"auto","created_at":"2026-02-09 16:15:46","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":6252477,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7350654/v1/eca115f7-78ff-4eb6-91c6-2427e44fbda0.pdf"},{"id":90380431,"identity":"1efc8034-7c47-4af2-9b55-c4f390803e17","added_by":"auto","created_at":"2025-09-02 06:43:19","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":31135,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable1GxEPAv6FINAL.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7350654/v1/d93017c33b6010311167d594.xlsx"},{"id":90382111,"identity":"41e8a09f-c6fe-4126-acb8-c3d7d6942021","added_by":"auto","created_at":"2025-09-02 06:51:37","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":2688082,"visible":true,"origin":"","legend":"","description":"","filename":"SUPPLEMENTARYTABLESANDFIGURES.docx","url":"https://assets-eu.researchsquare.com/files/rs-7350654/v1/2cd9d6e1b1331101512e0023.docx"}],"financialInterests":"Competing interest reported. Dr. Ulrich has as HCI Cancer Center Director oversight over research funded by several pharmaceutical companies but has not received funding directly herself. Dr. Peters was a consultant with AbbVie and her husband is holding individual stocks for the following companies: BioNTech SE – ADR, Amazon, CureVac BV, NanoString Technologies, Google/Alphabet Inc Class C, NVIDIA Corp, Microsoft Corp. Other authors declare that they have no conflict of interest.","formattedTitle":"Genetic risk factors modulate the association between physical activity and colorectal cancer","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eColorectal cancer (CRC) is a major global cause of morbidity and mortality. It is the third most commonly diagnosed cancer and second leading cause of death in the world, with more than 1.9\u0026nbsp;million incident cases and 0.9\u0026nbsp;million deaths in 2020 [1]. It is predicted that there will be 2.2\u0026nbsp;million and 3.2\u0026nbsp;million new CRC cases by 2030 [2] and 2040 [3], respectively, confirming CRC as a major continuing public health burden. The underlying etiology of CRC is multifactorial with a combination of genetic and environmental factors increasing the likelihood of developing CRC [4]. Among these risk factors, physical activity, a lifestyle factor, is an established protective factor against CRC [5\u0026ndash;9].\u003c/p\u003e\u003cp\u003eMultiple observational studies and several systematic reviews have shown that regular physical activity (occupational or leisure time) is a modifiable factor associated with lower CRC risk [10\u0026ndash;13]. In particular, the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Continuous Update Project reported lower CRC risk with increased physical activity and classified the evidence linking physical activity to lower CRC risk as \u0026ldquo;\u0026ldquo;strong\u0026rdquo; [5]. Despite the beneficial health effects of physical activity, a recent study reported that more than a quarter of all adults globally were not getting sufficient physical activity [14].\u003c/p\u003e\u003cp\u003eThere is substantial understanding of the mechanisms underlying the protective association of physical activity with CRC risk, for example, physical activity is known to have beneficial effects on skeletal muscle mass, immune function, sleep, and mental health [7, 15\u0026ndash;21]. Physical activity also reduces obesity (fat mass), which has a beneficial effect on CRC through a reduction in insulin resistance and inflammation, both of which have been associated with CRC development [7, 22\u0026ndash;24]. More recently, physical activity has been linked to improved gut microbiome diversity [25]. Further, non-modifiable genetic factors may play a role between physical activity and CRC. However, only a few gene-environment (GxE) interaction studies to date have investigated the association of physical activity with CRC risk according to genetic variants [26\u0026ndash;29], all of which were limited by small sample size or restricted to candidate genes/pathways.\u003c/p\u003e\u003cp\u003eUnderstanding the genetic factors that may influence the relationship between physical activity and CRC risk can offer novel insights into potential biological mechanisms of colorectal carcinogenesis, as well as better inform efforts to promote physical activity and potentially identify individualized physical activity prescriptions. We conducted the largest genome-wide GxE analysis to date, aiming to identify novel genetic variants that may modify the protective association between self-reported physical activity and CRC risk in order to obtain insight into potential mechanisms behind this association.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eStudy participants\u003c/h2\u003e\u003cp\u003eThe study included individual level genomic and epidemiologic data from three CRC consortia: the multi-centered Colon Cancer Family Registry (CCFR), the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and the Colorectal Cancer Transdisciplinary Study (CORECT), which have been previously described [30\u0026ndash;35]. Nested case-control sets were assembled from cohort studies. Control participants were matched on age, sex, and enrollment date/trial group, when applicable. CRC cases were defined as invasive colon or rectal tumors and were confirmed via multiple sources including electronic medical records, pathology reports, state or provincial cancer registries, and/or death certificates. For the small subset of advanced adenomas (7\u0026ndash;8%), matched controls were polyp-free and were confirmed by sigmoidoscopy or colonoscopy at the time of adenoma diagnosis. Each study was approved by relevant ethics committees or review boards from respective institutions. All participants provided written informed consent at recruitment.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eData harmonization\u003c/h3\u003e\n\u003cp\u003eData were collected and centralized at the GECCO consortium coordinating center at the Fred Hutchinson Cancer Center [34]. Briefly, data harmonization consisted of a multi-step procedure, in which common data elements (CDEs) were defined \u003cem\u003ea priori\u003c/em\u003e for data harmonization. Study questionnaires and data dictionaries were examined and, through an iterative process of communication with data contributors, elements were mapped to these CDEs. Definitions, permissible values, and standardized coding were implemented into a single database via SAS and T-SQL. Resulting data were checked for errors and outlying values within and between studies [36].\u003c/p\u003e\n\u003ch3\u003eEpidemiologic and lifestyle data collection\u003c/h3\u003e\n\u003cp\u003eInformation on demographic, lifestyle, and environmental factors as well as potential risk factors such as age at diagnosis or enrollment, sex, education level, smoking status, total energy consumption (kcal/day), and self-reported or measured weight and height were collected via in-person interviews or through structured self-administered questionnaires in each study. Total energy consumption was derived from the Food Frequency Questionnaires, with missing values imputed by study-sex-specific means. Body mass index (BMI) was calculated using the weight (kg) and height (m) of each participant.\u003c/p\u003e\n\u003ch3\u003ePhysical activity exposure measure\u003c/h3\u003e\n\u003cp\u003eInformation on physical activity was obtained from structured questionnaires, such as the International Physical Activity Questionnaire (IPAQ) short form [37], European Prospective Investigation into Cancer and Nutrition (EPIC) physical activity questionnaire, and Nurses' Health Study physical activity questionnaire, among others. Physical activity was estimated in metabolic equivalent tasks hours per week (MET-h/wk), which was derived for each participant, to determine the approximate average amount of time per week that the individual spent in leisure activities or all activities if leisure was not specified.\u003c/p\u003e\u003cp\u003eModerate activity was defined as 3.5 to 6 MET-h/wk and vigorous activities as \u0026ge;\u0026thinsp;6 MET-h/wk [38]. Thus, at least 8.75 MET-h/wk approximately corresponds to the current physical activity guidelines of a minimum of 150 minutes (=\u0026thinsp;2.5 hours) of moderate or 75 minutes of vigorous activity per week as recommended for individuals with cancer or for cancer prevention [39\u0026ndash;42]. Based on these guidelines and previously published literature in CRC [43\u0026ndash;45], the participants in the present study were categorized into two groups: active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk; reference category). Because the majority of the participants were active, we also calculated study- and sex-specific quartiles for physical activity as a secondary variable, where the quartile groups were coded as 1, 2, 3, or 4, respectively. This variable was treated as continuous (change in one quartile) when assessing the association between physical activity and CRC, and as categorical (1st quartile as reference group) in the genome-wide scans.\u003c/p\u003e\n\u003ch3\u003e\u003c/h3\u003e\n\u003cdiv class=\"Heading\"\u003e\u003cb\u003eGenotyping, quality control, and imputation\u003c/b\u003e\u003c/div\u003e\u003cp\u003eDetailed information on genotyping, imputation, and quality control have been described previously [30, 32]. In brief, genotyped single nucleotide polymorphisms (SNPs) were excluded based on deviation from Hardy-Weinberg Equilibrium (p\u0026thinsp;\u0026lt;\u0026thinsp;1x10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e), low call rate (\u0026lt;\u0026thinsp;95\u0026ndash;98%), discrepancies between reported and genotypic sex, and discordant calls between duplicates. Autosomal SNPs in all studies were imputed to the Haplotype Reference Consortium (HRC) r1.1 (2016) panel using the University of Michigan Imputation Server [46] and treated as dosage for data management and analyses using R package BinaryDosage [47]. Imputed common SNPs were excluded if they had low imputation quality (\u003cem\u003eR\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.8) and pooled minor allele frequency (MAF)\u0026thinsp;\u0026le;\u0026thinsp;1%. After quality control, a total of over \u0026gt;\u0026thinsp;7.2\u0026nbsp;million SNPs were used for the gene-environment interaction analysis, noticeably with high redundancy due to linkage disequilibrium (LD).\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eSample size\u003c/h2\u003e\u003cp\u003eAnalyses were limited to individuals of European ancestry, based on self-reported race and clustering of principal components (PCs) with 1000 Genomes EUR superpopulations [48]. Participants were excluded based on cryptic relatedness or duplicates (prioritizing cases and/or individuals genotyped on the better platform), and genotyping/imputation errors. We also excluded studies that did not collect physical activity data. The pooled sample size for the study- and sex-specific quartile physical activity variable was 42,602 participants from 31 studies (71% prospective cohort studies). For the dichotomous active-inactive physical activity variable, with 8.75 MET-h/wk as the cutoff value, the final pooled sample size was 39,992 participants from 27 studies (74% prospective cohort studies) (\u003cb\u003eSupplementary Table\u0026nbsp;1\u003c/b\u003e).\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eStatistical Analyses\u003c/h3\u003e\n\u003cp\u003eTo evaluate the main effects of physical activity on CRC risk, logistic regression models were conducted for each study, with adjustment for age at diagnosis or enrollment, sex, and total energy consumption (when available). Models with genetic variables were further adjusted for the first three PCs of genetic ancestry to account for potential population substructure. The study-specific results were combined using random-effects meta-analysis methods (Hartung-Knapp) to obtain summary odds ratios (ORs) and 95% confidence intervals (CIs) [49]. The heterogeneity p-values were calculated using Cochran\u0026rsquo;s Q statistics [50], while funnel plots identified studies with outlying ORs for potential exclusion and sensitivity analyses. Additional models were fitted, stratified by study design (case-control vs. cohort), sex, and tumor site (proximal colon, distal colon, rectal). All meta-analyses were performed using the R package Meta [51].\u003c/p\u003e\u003cp\u003eGenome-wide interaction scans of common markers were conducted in the overall study population to maximize power. For the purposes of this study, \u003cem\u003eE\u003c/em\u003e indicates physical activity, \u003cem\u003eG\u003c/em\u003e indicates a particular SNP, \u003cem\u003eD\u003c/em\u003e indicates CRC disease status, and \u003cem\u003eC\u003c/em\u003e refers to a set of adjustment covariables. We utilized not only the traditional logistic regression test of GxE (1-degree of freedom test; 1-d.f.), but also the more powerful joint 3-d.f. test [52, 53] and two-step EDGE method [54\u0026ndash;56]. The R package GxEScanR [57] was used to perform these analyses.\u003c/p\u003e\u003cp\u003eFor the 1-d.f. test, we examined multiplicative interactions by fitting a traditional logistic regression model including an interaction term in the form: \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:logit\\left({Pr}\\left(D=1|G\\right)\\right)={\\beta\\:}_{0}+{\\beta\\:}_{G}G+{\\beta\\:}_{E}E+\\:{\\beta\\:}_{GxE}GxE+{\\beta\\:}_{C}C\\)\u003c/span\u003e\u003c/span\u003e, where \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:H0:{\\beta\\:}_{GxE}=0\\)\u003c/span\u003e\u003c/span\u003e tests potential departures from multiplicative associations of \u003cem\u003eE\u003c/em\u003e and \u003cem\u003eG\u003c/em\u003e on \u003cem\u003eD\u003c/em\u003e.\u003c/p\u003e\u003cp\u003eWe also performed a joint test of association, which can improve power to detect disease susceptibility loci in a wider range of circumstances by accounting for GxE interactions, e.g., in circumstances where susceptibility loci affect only individuals with certain environmental exposure profiles [53, 58]. For this we used the 3-d.f. test of the joint null hypothesis \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:H0={\\beta\\:}_{G}={\\beta\\:}_{GxE}={\\gamma\\:}_{G}=0\\)\u003c/span\u003e\u003c/span\u003e, where \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:\\:{\\beta\\:}_{G}\\:\\text{a}\\text{n}\\text{d}{\\:\\beta\\:}_{GxE}\\)\u003c/span\u003e\u003c/span\u003eare the main and interaction effects from the logistic model above and \u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\(\\:{\\gamma\\:}_{G}\\)\u003c/span\u003e\u003c/span\u003e represents the association between \u003cb\u003eG\u003c/b\u003e and \u003cb\u003eE\u003c/b\u003e in the combined case-control sample [53, 59].\u003c/p\u003e\u003cp\u003eWe further implemented the two-step EDGE method that assesses GxE interaction tests (step 2) based on ranks of an independent filtering or ranking statistic (step 1) [56]. The two-step method can decrease the multiple testing burden and improve power to detect interaction loci [56, 59, 60], provided that steps 1 and 2 are independent. The original approach uses step 1 ranks to prioritize and partition SNPs into exponentially larger bins of fixed sizes and increasingly more stringent step- 2 significance thresholds. However, when analyzing imputed SNPs, highly correlated markers from the same loci fill the top bins, thereby diminishing statistical power. To address this issue, the original weighted hypothesis-testing framework [61] was modified to accommodate bins of varying sizes while appropriately controlling for type I error [55]. In particular, SNPs were partitioned into bins based on step 1 p-value thresholds \u003cem\u003ein expectation\u003c/em\u003e, which were calculated using the original predetermined bin sizes (initial bin size of 5 and overall alpha\u0026thinsp;=\u0026thinsp;0.05) with assumed uniform distribution of 1\u0026nbsp;million independent tests. For step 2 GxE testing, the influx of correlated markers into each bin was accounted for by correcting for the effective number of tests, which was estimated using principal component analysis (PCA) performed on bin-specific genotype correlation matrices [54, 55, 62]. This modification reduces multiple testing burden and improves statistical power, while preserving the overall type I error rate at 5%. For any SNP achieving significance at the overall type I error rate, we computed its corresponding SNP-specific p-value accounting for both steps 1 and 2 of the EDGE procedure, to allow direct comparison to the standard GWAS threshold of 5 x 10\u003csup\u003e\u0026minus;\u0026thinsp;8\u003c/sup\u003e [62].\u003c/p\u003e\u003cp\u003eTo follow-up statistically significant interactions, we estimated stratified ORs by modeling physical activity in relation to CRC within genotypic groups and the per-allele increase in genotype in relation to CRC stratified by physical activity. We also assessed the extent of genomic inflation by creating quantile-quantile (Q-Q) plots and calculating the genomic inflation factor (lambda). Additionally, we calculated lambda\u003csub\u003e1000\u003c/sub\u003e, which scales the genomic inflation factor to an equivalent study of 1000 cases and 1000 controls, since as lambda scales according to the sample size [63, 64].\u003c/p\u003e\u003cp\u003eTo explore variation in GxE effect strengths of association, we also conducted stratified analyses for novel findings by study design, sex, and tumor site. We conducted a sensitivity analysis including the interaction terms GxBMI and E(=\u0026thinsp;physical activity)xBMI in the model, because BMI it is a potential confounder in the physical activity\u0026minus;CRC association [65].\u003c/p\u003e\n\u003ch3\u003eFunctional follow-up\u003c/h3\u003e\n\u003cp\u003e Regional plots for all statistically significant findings were generated using the command- line version (standalone) of LocusZoom v1.3 [66] to examine, in depth, the magnitudes of association, the extent of association signal due to LD, and chromosomal position of findings relative to genes in the given region. Measures of LD were estimated using study population controls. The putative functional role of these SNPs and those in LD (R\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;\u0026gt;\u0026thinsp;0.5) at 500 kb flanking regions were examined relative to their potential contribution to regulate gene expression by their: i) direct association with expression of nearby genes (expression quantitative trait loci (eQTLs); and ii) physical location in regions of chromatin accessibility or histone modifications (variant enhancer loci).\u003c/p\u003e\u003cp\u003ePossible eQTL relationships were explored using: i) the Genotype-Tissue Expression (GTEx v8); and ii) the University of Barcelona and University of Virginia genotyping and RNA sequencing project (BarcUVa-Seq) dataset, which includes normal colon tissue samples from 445 healthy individuals [67]. In addition, the BarcUVa-Seq project has data on physical activity in 352 (79%) participants, which we also used to test both specific eQTLs for physical activity status (active vs. inactive; study- and sex-specific quartile variable) and interactions between SNPs and physical activity on gene expression. The BarcUVA-Seq models were adjusted for age (years), sex, sequencing batch (one to four), and tissue location (left, right, transverse, missing). The putative functional role of SNPs and those in LD (r2\u0026thinsp;\u0026gt;\u0026thinsp;0.2) and MAF\u0026thinsp;\u0026gt;\u0026thinsp;0.01 at 500kb flanking regions were investigated relative to their potential contribution to regulate gene expression by their physical location in regions of chromatin accessibility or histone modifications (variant enhancer loci). We annotated only suggestive eQTLs, i.e., those having a nominal p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e\u003cp\u003eDetails of the functional- annotations analyses have been previously published [68, 69]. Briefly, we used an assay for transposase-accessible chromatin with sequencing (ATAC-seq), DNaseI Hypersensitivity (DHS)-seq, H3K27ac histone ChIP-seq, H3K4me1 histone ChIP-seq datasets of primary tissue from healthy colon and primary-tumor primary tissue samples containing active enhancer elements from Scacheri et al. [70], as well as from three CRC cell lines (SW480, HCT116, COLO205). These datasets were processed through ENCODE ATAC-seq/DNASE-seq [71] and histone ChIP-seq pipelines [72] to perform alignment and peak calling.\u003c/p\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003eGxE analyses for rare variants\u003c/h2\u003e\u003cp\u003eTo assess the potential contribution of rare SNPs, we also performed a gene-set-based aggregate tests only for rare SNPs using the Mixed effects Score Test for Interactions (MiSTi) approach [73] as a secondary analysis, as the power for rare SNPs testing usually is low. We examined the interactions of physical activity and aggregated rare SNP sets at the gene and enhancer level using MiSTi (MiSTi R package). We used a Fisher\u0026rsquo;s combination approach under MiSTi (fMiSTi) to discover GxE interactions [73], after adjusting for age, sex, study, and the first three PCs. Because 25,000 gene regions were tested and this was a secondary analysis, interactions with p\u0026thinsp;\u0026lt;\u0026thinsp;2x10\u003csup\u003e\u0026minus;\u0026thinsp;6\u003c/sup\u003e were considered statistically significant, while whereas those with p\u0026thinsp;\u0026lt;\u0026thinsp;1x10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e were considered suggestive.\u003c/p\u003e\u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003eStudy population characteristics\u003c/h2\u003e\u003cp\u003eThe total sample size was n\u0026thinsp;=\u0026thinsp;39,992 (16,383 CRC cases and 23,609 controls), with 76% classified as active (i.e., \u0026ge;\u0026thinsp;8.75 MET-h/wk). Detailed descriptive characteristics of the study population are presented in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Compared to controls, CRC cases were more likely to be older, female, ever smokers, have a higher BMI and total energy consumption, and have a lower education level (each p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Descriptive characteristics of the study population for the secondary physical activity variable assessed as study- and sex-specific quartiles are provided in \u003cb\u003eSupplementary Table\u0026nbsp;2.\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eDescriptive characteristics of all study participants by colorectal cancer case-control status with available physical activity data.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"4\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCharacteristics\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eCases\u003c/p\u003e\u003cp\u003e(N\u0026thinsp;=\u0026thinsp;16,383)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eControls\u003c/p\u003e\u003cp\u003e(N\u0026thinsp;=\u0026thinsp;23,609)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003eAge (median imputed)\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMean (SD)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e65.0 (\u0026plusmn;\u0026thinsp;9.4)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e63.4 (\u0026plusmn;\u0026thinsp;8.3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eSex\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFemale\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e8,677 (53%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e12,005 (51%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMale\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7,706 (47%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e11,604 (49%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eTotal energy consumption (kcal/day; mean imputed)\u003c/b\u003e\u003csup\u003e\u003cb\u003eb,c\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMean (SD)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1,967 (\u0026plusmn;\u0026thinsp;713)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1,910 (\u0026plusmn;\u0026thinsp;680)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBMI (kg/m\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u003cb\u003e)\u003c/b\u003e\u003csup\u003e\u003cb\u003ec\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMean (SD)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e27.2 (\u0026plusmn;\u0026thinsp;4.7)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e26.9 (\u0026plusmn;\u0026thinsp;4.5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eFamily history of colorectal cancer\u003c/b\u003e\u003csup\u003e\u003cb\u003ec\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e10,430 (64%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e12,945 (55%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.06\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e2,295 (14%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,685 (11%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEducation level (highest completed)\u003c/b\u003e\u003csup\u003e\u003cb\u003ec\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLess than High School\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3,070 (19%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3,488 (15%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eHigh School/GED\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3,366 (21%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3,161 (13%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSome College\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e3,476 (21%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e5,783 (24%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCollege/Graduate School\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5,601 (34%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e8,488 (36%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEver smoker\u003c/b\u003e\u003csup\u003e\u003cb\u003ec\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNo\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7,050 (43%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e11,479 (49%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYes\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9,086 (55%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e11,862 (50%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e\u003cp\u003eNOTE: Data might not add to 100% because of rounding.\u003c/p\u003e\u003cp\u003eAbbreviations: SD, standard deviation; BMI, Body-Mass-Index; GED, General Educational Development Test.\u003c/p\u003e\u003cp\u003ePhysical activity categorized as active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk; reference category) dichotomous variable.\u003c/p\u003e\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Age was assessed at diagnosis or enrollment.\u003c/p\u003e\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Calculations exclude individuals with missing total energy intake information.\u003c/p\u003e\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Missing values not shown.\u003c/p\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 are statistically significant.\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\u003ch2\u003ePhysical activity and CRC risk\u003c/h2\u003e\u003cp\u003eWe observed that being active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk) was associated with a 15% risk reduction in CRC in the overall meta-analysis (OR\u0026thinsp;=\u0026thinsp;0.85; 95% CI\u0026thinsp;=\u0026thinsp;0.81\u0026minus;0.90; \u003cb\u003eSupplementary Fig.\u0026nbsp;1A; Supplementary Table\u0026nbsp;3\u003c/b\u003e). Sensitivity analyses showed even greater risk reduction for case-control studies (OR\u0026thinsp;=\u0026thinsp;0.75; 95% CI\u0026thinsp;=\u0026thinsp;0.66\u0026minus;0.85) compared to cohort-based studies (OR\u0026thinsp;=\u0026thinsp;0.88; 95% CI\u0026thinsp;=\u0026thinsp;0.83\u0026minus;0.93). No evidence for heterogeneity was observed across all studies (\u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.64; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%;) or among case-control (\u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.36; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;9%) or cohort-based studies (\u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.91; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%). Further, analysis stratified by sex showed a risk reduction in both men (OR\u0026thinsp;=\u0026thinsp;0.83; 95% CI\u0026thinsp;=\u0026thinsp;0.76\u0026minus;0.90; \u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.56; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%) and women (OR\u0026thinsp;=\u0026thinsp;0.87; 95% CI\u0026thinsp;=\u0026thinsp;0.81\u0026minus;0.94; \u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.86; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%) when comparing active vs. inactive participants. For tumor site, the strongest inverse associations were observed for distal colon (OR\u0026thinsp;=\u0026thinsp;0.77, 95% CI\u0026thinsp;=\u0026thinsp;0.71\u0026minus;0.84; \u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.64; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%) and proximal colon (OR\u0026thinsp;=\u0026thinsp;0.84, 95% CI\u0026thinsp;=\u0026thinsp;0.81\u0026minus;0.90; \u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.46; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0%), but not for rectal cancer (OR\u0026thinsp;=\u0026thinsp;0.94, 95% CI\u0026thinsp;=\u0026thinsp;0.85\u0026minus;1.04; \u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e=0.27; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;15%) comparing active vs. inactive participants. For physical activity measured as study- and sex-specific quartiles (treated as a continuous variable), we observed similar risk reductions for the overall meta-analysis as well as for stratified analysis by sex (\u003cb\u003eSupplementary Fig.\u0026nbsp;1B; Supplementary Table\u0026nbsp;4\u003c/b\u003e). In dose-response (per-quartile) analyses, inverse associations were also observed for rectal cancer (per quartile OR\u0026thinsp;=\u0026thinsp;0.95; 95% CI\u0026thinsp;=\u0026thinsp;0.92\u0026ndash;0.98; P\u003csub\u003ehet\u003c/sub\u003e\u0026lt;0.001; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;54%) as well as for distal and proximal colon, with some inter-study heterogeneity observed for case-control studies (\u003cem\u003eP\u003c/em\u003e\u003csub\u003ehet\u003c/sub\u003e\u0026lt;0.001; \u003cem\u003eI\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;74%). As we found statistically significant associations between physical activity and CRC for the overall population without significant evidence for heterogeneity, we conducted genome-wide GxE testing in the overall study population to maximize power.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003eGenome-wide physical activity-interaction scans for CRC risk\u003c/h2\u003e\u003cp\u003eThe quantile-quantile (Q-Q) plot for the traditional gene-physical activity interactions for CRC risk using 1-d.f. analysis did not show p-value inflation for either primary and or secondary physical activity variables (\u003cb\u003eSupplementary Fig.\u0026nbsp;2\u003c/b\u003e).\u003c/p\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e summarizes the statistically significant gene-physical activity interactions identified. Using the two-step EDGE method and the dichotomous physical activity variable (active vs. inactive), we identified statistically significant interactions for 5 SNPs, all of them in LD, on chromosome 15q13.3 located in the intergenic region between Gremlin 1 (\u003cem\u003eGREM1\u003c/em\u003e) and Secretogranin V (\u003cem\u003eSCG5\u003c/em\u003e) genes.[74] Among these SNPs with statistically significant interactions, we report only on the interaction of SNP rs4779584 with physical activity in this study (two-step p-value\u0026thinsp;=\u0026thinsp;2.6x10\u003csup\u003e\u0026minus;\u0026thinsp;8\u003c/sup\u003e; Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e), as this SNP was supported by prior evidence on the association with CRC as main effect (per T allele OR: active\u0026thinsp;=\u0026thinsp;1.20; 95% CI\u0026thinsp;=\u0026thinsp;1.10\u0026ndash;1.20 vs. inactive\u0026thinsp;=\u0026thinsp;1.00; 95% CI\u0026thinsp;=\u0026thinsp;0.93\u0026minus;1.10; Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).[75] This result was robust in a sensitivity analysis that further accounted for BMI and interactions with BMI, as well as age, sex, study type, total energy consumption, and the first three PCs of genetic ancestry. Specifically, these additional adjustments caused less than a 2% change in the GxPA interaction estimates. Analysis stratified by rs4779584 genotype showed that participants who were physically active vs. inactive had 20% lower CRC risk among those who were carriers of CC (OR\u0026thinsp;=\u0026thinsp;0.80; 95% CI\u0026thinsp;=\u0026thinsp;0.75\u0026minus;0.85; p\u0026thinsp;=\u0026thinsp;1.6x10\u003csup\u003e\u0026minus;\u0026thinsp;11\u003c/sup\u003e), while this risk reduction was diminished among those carrying the CT (OR\u0026thinsp;=\u0026thinsp;0.92; 95% CI\u0026thinsp;=\u0026thinsp;0.84\u0026minus;1.00) and TT (OR\u0026thinsp;=\u0026thinsp;1.30; 95% CI\u0026thinsp;=\u0026thinsp;1.00-1.70;) genotypes (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e; Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). We observed similar interaction effects when analyses were stratified for study type, sex, or tumor site (\u003cb\u003eSupplementary Table\u0026nbsp;5\u003c/b\u003e).\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eResults of genome-wide interaction analyses with physical activity for colorectal cancer risk.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"12\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u003cp\u003ePhysical Activity Variable\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003eSNP\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eChr\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eBP Position\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eLocus\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eClosest Gene\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003cp\u003eAllele\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u003cp\u003eAlternate Allele\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c9\"\u003e\u003cp\u003eAlternate Allele frequency\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c10\"\u003e\u003cp\u003eType\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c11\"\u003e\u003cp\u003eStatistical Method\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c12\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value GxE\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eActive / Inactive\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ers4779584\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e15\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e32994756\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e15q13.3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e0.20\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eIntergenic variant\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003eTwo-step EDGE\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e\u003cb\u003e2.6x10\u003c/b\u003e\u003csup\u003e\u003cb\u003e\u0026minus;\u0026thinsp;8\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eQuartiles\u003csup\u003e\u003cb\u003ec\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003ers56906466\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e20\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e49693755\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e20q4.5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cem\u003eKCNG1\u003c/em\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003eT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003eC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e0.06\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003eIntron\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e1-d.f. test\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e\u003cb\u003e3.5x10\u003c/b\u003e\u003csup\u003e\u003cb\u003e\u0026minus;\u0026thinsp;8\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"12\" nameend=\"c12\" namest=\"c1\"\u003e\u003cp\u003eAbbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; BP Position, base pair position based on NCBI Build 37; 1-d.f., 1-degree of freedom.\u003c/p\u003e\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Physical activity categorized as active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk; reference category).\u003c/p\u003e\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e \u003cem\u003eP\u003c/em\u003e-value corresponds to the interaction between genetic variants (G) and physical activity (E) on risk of colorectal cancer in the combined case-control population based on the indicated statistical method.\u003c/p\u003e\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Physical activity assessed as study- and sex-specific quartiles.\u003c/p\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-values that are statistically significant are indicated in bold text.\u003c/p\u003e\u003cp\u003eNotes: Directly genotyped SNPs were coded as 0, 1, or 2 copies of the count allele. Imputed SNPs were coded as expected gene dosage. Multiplicative interaction terms were modelled as the product of PA and each SNP of interest.\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eAssociations between physical activity for colorectal cancer risk stratified by genotypes of SNPs of interest.\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"13\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c13\" colnum=\"13\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003eSNP\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e\u003cp\u003ePhysical Activity\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"3\" nameend=\"c5\" namest=\"c3\"\u003e\u003cp\u003eHomozygous non-carriers\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u003cp\u003eHeterozygous\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"3\" nameend=\"c11\" namest=\"c9\"\u003e\u003cp\u003eHomozygous carries of the alternate/minor allele\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colspan=\"2\" nameend=\"c13\" namest=\"c12\"\u003e\u003cp\u003ePer alternative allele within strata of Physical Activity categories\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eN (Ca/Co)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eOR (95% CI)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eN (Ca/Co)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eOR (95% CI)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c9\"\u003e\u003cp\u003eN (Ca/Co)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c10\"\u003e\u003cp\u003eOR (95% CI)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c11\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c12\"\u003e\u003cp\u003eOR (95% CI)\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c13\"\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c5\" namest=\"c3\"\u003e\u003cp\u003eCC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u003cp\u003eCT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c11\" namest=\"c9\"\u003e\u003cp\u003eTT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ers4779584\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eInactive\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e2,537/3,642\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1.00 (Ref.)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e1,304/1,806\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e1.00 (0.95\u0026ndash;1.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.40\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e137/228\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.87 (0.69\u0026ndash;1.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.23\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e1.00 (0.93\u0026ndash;1.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e0.98\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eActive\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7,701/11,960\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.80 (0.75\u0026ndash;0.85)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.6x10\u003csup\u003e\u0026minus;\u0026thinsp;11\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e4,155/5,372\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.95 (0.89-1.00)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.19\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e549/601\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.10 (0.99\u0026ndash;1.30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.08\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e1.20 (1.10\u0026ndash;1.20)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e2.0x10\u003csup\u003e\u0026minus;\u0026thinsp;15\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eActive vs. inactive (by genotype)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.80 (0.75\u0026ndash;0.85)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.6x10\u003csup\u003e\u0026minus;\u0026thinsp;11\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.92 (0.84-1.00)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.05\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.30 (1.00-1.70)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.04\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c5\" namest=\"c3\"\u003e\u003cp\u003eTT\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c8\" namest=\"c6\"\u003e\u003cp\u003eTC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colspan=\"3\" nameend=\"c11\" namest=\"c9\"\u003e\u003cp\u003eCC\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ers56906466\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ1\u003csup\u003e\u003cb\u003eb\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4,168/5,290\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1.00 (Ref.)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e443/715\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.77 (0.67\u0026ndash;0.87)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e8.0x10\u003csup\u003e\u0026minus;\u0026thinsp;5\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e20/19\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.10 (0.56\u0026ndash;2.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.81\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e0.77 (0.68\u0026ndash;0.88)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e1.4x10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ2\u003csup\u003e\u003cb\u003eb\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e4,085/5,745\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.91 (0.85\u0026ndash;0.96)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.002\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e481/710\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.87 (0.76\u0026ndash;0.99)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e13/25\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.61 (0.3\u0026ndash;1.20)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.16\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e0.93 (0.82\u0026ndash;1.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e0.28\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ3\u003csup\u003e\u003cb\u003eb\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3,792/5,896\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.81 (0.76\u0026ndash;0.86)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e6.8x10\u003csup\u003e\u0026minus;\u0026thinsp;12\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e469/669\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.87 (0.77-1.00)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.047\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e21/26\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.00 (0.56\u0026ndash;1.90)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.96\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e1.10 (0.99\u0026ndash;1.30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e0.08\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ4\u003csup\u003e\u003cb\u003eb\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e3,342/5,564\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.77 (0.72\u0026ndash;0.82)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.1x10\u003csup\u003e\u0026minus;\u0026thinsp;16\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e442/637\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e0.94 (0.82\u0026ndash;1.10)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.35\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e17/13\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.90 (0.91\u0026ndash;4.20)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.09\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e1.30 (1.10\u0026ndash;1.50)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u003cp\u003e5.7x10\u003csup\u003e\u0026minus;\u0026thinsp;4\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ2 vs. Q1 (by genotype)\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.91 (0.85\u0026ndash;0.96)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.002\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e1.10 (0.95\u0026ndash;1.30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.16\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.56 (0.21\u0026ndash;1.50)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.23\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ3 vs. Q1 (by genotype)\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.81 (0.76\u0026ndash;0.86)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e6.8x10\u003csup\u003e\u0026minus;\u0026thinsp;12\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e1.10 (0.96\u0026ndash;1.40)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.14\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.93 (0.38\u0026ndash;2.30)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.88\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003eQ4 vs. Q1 (by genotype)\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.77 (0.72\u0026ndash;0.82)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.1x10\u003csup\u003e\u0026minus;\u0026thinsp;16\u003c/sup\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e1.20 (1.00-1.50)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u003cp\u003e0.03\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u0026minus;\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.80 (0.65\u0026ndash;4.90)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.26\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c13\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"13\" nameend=\"c13\" namest=\"c1\"\u003e\u003cp\u003eAbbreviations: SNP, single nucleotide polymorphism; PA, physical activity; N, number; Ca/Co, case/control; OR, odds ratio; 95% CI, 95% confidence interval.\u003c/p\u003e\u003cp\u003eCase/control counts were calculated by imputed genotype probabilities.\u003c/p\u003e\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Physical activity categorized as active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk; reference category)\u003c/p\u003e\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Physical activity, assessed as study- and sex-specific quartiles.\u003c/p\u003e\u003cp\u003e\u003cem\u003eP\u003c/em\u003e-values that are statistically significant are indicated in bold text.\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eThe analysis of physical activity assessed as study- and sex-specific quartiles revealed an interaction with one SNP (rs56906466) on chromosome 20q4.5 located near the Potassium Voltage-Gated Channel Modifier Subfamily G Member 1 (\u003cem\u003eKCNG1\u003c/em\u003e) gene, using the traditional 1-d.f. test (GxE p-value\u0026thinsp;=\u0026thinsp;3.5x10\u003csup\u003e\u0026minus;\u0026thinsp;8\u003c/sup\u003e; Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e; \u003cb\u003eSupplementary Fig.\u0026nbsp;3B\u003c/b\u003e). This result was still consistent in a sensitivity analysis that also considered BMI and interactions with BMI along with age, sex, study type, total energy consumption, and the first three PCs of genetic ancestry. As in the previous sensitivity analysis, these adjustments resulted in less than a 2% variation in the GxPA interaction estimates. Analysis stratified by rs56906466 genotype showed statistically significantly lower CRC risk with increases in physical activity, especially when comparing the highest quartile (Q4) to the lowest quartile (Q1), among those who were carriers of TT (OR\u0026thinsp;=\u0026thinsp;0.77; 95% CI\u0026thinsp;=\u0026thinsp;0.72\u0026minus;0.82; p\u0026thinsp;=\u0026thinsp;1.1x10\u003csup\u003e\u0026minus;\u0026thinsp;16\u003c/sup\u003e). The corresponding inverse associations were not observed for those with TC (Q4 vs. Q1: OR\u0026thinsp;=\u0026thinsp;1.20; 95% CI\u0026thinsp;=\u0026thinsp;1.00\u0026minus;1.50; p\u0026thinsp;=\u0026thinsp;0.03) and CC (Q4 vs. Q1: OR\u0026thinsp;=\u0026thinsp;1.80; 95% CI\u0026thinsp;=\u0026thinsp;0.65\u0026minus;4.90; p\u0026thinsp;=\u0026thinsp;0.26) genotypes (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Similar interactions were observed when analyses were stratified by study type, sex, or tumor site (\u003cb\u003eSupplementary Table\u0026nbsp;5\u003c/b\u003e). No other statistically significant interactions were observed (data not shown). Additionally, the GxE analyses for rare variants did not identify any statistically significant interactions. There was also no significant LD-based correlation between rs4779584 and rs56906466 (correlation coefficient, \u003cem\u003er\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.001).\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003eFunctional follow-up\u003c/h2\u003e\u003cp\u003eFunctional annotation analyses around rs4779584 and rs56906466 showed enhanced activities. The SNP rs4779584 and correlated SNPs showed peaks in both normal (i.e., ATAC-seq, H3K4me1) and colon tumor samples (i.e., tumor DHS, tumor H3K27ac) as well as in cancer cell lines (i.e., H3K27ac, H3K4me1). The SNP rs56906466, although not correlated with other SNPs, was identified as a variant enhancer for tumor DHS and cell line DHS (\u003cb\u003eSupplementary Figs.\u0026nbsp;4\u0026ndash;5\u003c/b\u003e).\u003c/p\u003e\u003cp\u003eTwo independent sources of eQTLs analyses were used to expand on the regulatory roles of SNPs rs4779584 and rs56906466. The SNP rs4779584 was observed to be an eQTL in the GTEx v8 compendium as it modified the expression of \u003cem\u003eGREM1\u003c/em\u003e in liver and pancreas, \u003cem\u003eSCG5\u003c/em\u003e in liver, and RP11- 758N13.1 in brain, cultured fibroblast, liver, and pancreas tissues. We did not observe any statistically significant eQTL findings for SNP rs56906466.\u003c/p\u003e\u003cp\u003eIn relation to the BarcUVa-Seq dataset, which provides colon-specific eQTLs, the SNP in the 15q13.3 region did not modify the expression of \u003cem\u003eFNM1, GREM1, SCG5\u003c/em\u003e, or other genes in the region (\u003cb\u003eSupplementary Fig.\u0026nbsp;4)\u003c/b\u003e. Likewise, the models tested in this dataset on the interaction with physical activity measured in the subjects did not reach statistical significance. The same approach was used to assess whether the SNP rs56906466 and the interaction term had eQTL effects on gene expression, but no statistically significant results were observed.\u003c/p\u003e\u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eTo our knowledge, this is the largest genome-wide study conducted to date to investigate the interactions between variants across the genome and self-reported, harmonized physical activity data. Consistent with previous studies and the WCRF, we observed a statistically significant 15% risk reduction in CRC due to physical activity, similar in magnitude to that previously observed [5, 10\u0026ndash;13]. Our analyses identified two novel, statistically significant GxE interactions for physical activity \u0026ndash; SNPs rs4779584 and rs56906466 significantly modified the association between physical activity and CRC risk.\u003c/p\u003e\u003cp\u003eThe SNP rs4779584, located in the 15q33.3 region, lies between the \u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e genes and has been previously found to contribute to CRC susceptibility [31, 74, 76\u0026ndash;79]. Carrying the T allele in rs4779584 has been reported to be associated with an increased CRC risk of 1.26 (95% CI\u0026thinsp;=\u0026thinsp;1.19\u0026minus;1.34) as compared to the C allele [80]. In our study, we found that physical activity was significantly associated with a lower risk of CRC only among those with the C allele. \u003cem\u003eGREM1\u003c/em\u003e encodes gremlin 1, which is a signaling protein involved in several pathways relevant to CRC, including the transforming growth factor-β (TGF-β) pathway which has been implicated in tumor invasion and metastasis [81]. \u003cem\u003eGREM1\u003c/em\u003e is also a proangiogenic factor, suggesting a possible role in cancer development when upregulated [82]. Additionally, Gremlin 1 is an insulin antagonist with elevated levels in type 2 diabetes [83], and has been linked to bone morphogenetic proteins (BMPs) signaling imbalance, which accelerates tumor cell proliferation [84], and is associated with inflammatory processes independently of BMPs [85, 86], \u003cem\u003eSCG5\u003c/em\u003e encodes secretogranin V (also named 7B2 protein or SGNE1), an essential neuroendocrine signaling molecule that plays a role in cellular proliferation [87, 88]. Although \u003cem\u003eSCG5\u003c/em\u003e is associated with polyposis syndromes which is linked with CRC risk [89], its direct role in CRC is not as well characterized as compared to \u003cem\u003eGREM1\u003c/em\u003e\u0026rsquo;s role in CRC [90]. Further, some studies have also reported a role of \u003cem\u003eSCG5\u003c/em\u003e in BMI modulation [91, 92]. The identified interactions suggest that the CRC risk reduction due to physical activity may be related to one or several more of these above-mentioned pathways.\u003c/p\u003e\u003cp\u003eThere are only a small number of GWAS studies that have identified genetic loci associated with physical activity [93, 94], with one preclinical study suggesting that exercise training epigenetically reprograms \u003cem\u003eGREM1\u003c/em\u003e expression [95]. However, to our knowledge, no prior studies have reported an interaction between rs4779584 and physical activity on CRC risk. The epidemiologic evidence indicating the beneficial effect of physical activity on CRC risk is extensive, and several biological mechanisms have been identified or proposed, including in some intervention studies, such as physical activity\u0026rsquo;s effect on immune system, systemic inflammatory markers, energy regulation, hormones levels, insulin resistance, and gut microbial composition [7, 96\u0026ndash;98]. Related to our findings, a randomized trial conducted in obese patients who followed different resistance training protocols observed significant reductions in plasma gremlin 1 and C-reactive protein levels compared to a control group [99]. Additionally, myokines (i.e., cytokines), such as myostatin (member of the TGF-β family) or interleukin-6, are secreted by the skeletal muscle in response to intensity training [100, 101]. The effect of regular exercise on \u003cem\u003eSCG5\u003c/em\u003e, the other gene close to the SNP rs4779584 that showed interactions with physical activity on CRC risk, has been investigated in experimental studies using animal models. However, the results were inconclusive, with one study reported non-significantly decreased SCG5 expression, while the other study reported significantly increased expression levels [102, 103]. Future studies are warranted to describe the plausible biological mechanism by which SNP rs4779584 interacts with physical activity and modifies CRC risk, but on the basis of our findings, genetic markers in this region showed enhanced activity in both normal and tumor samples suggesting a potential regulatory role on transcription of adjacent genes. Consistent with this, we observed that SNP rs4779584 modified the expression of \u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e in pancreas and liver, but not in colon tissue.\u003c/p\u003e\u003cp\u003eWe also discovered a new locus rs56906466 located near \u003cem\u003eKCNG1\u003c/em\u003e that has not been previously associated with CRC, physical activity, or its interaction with physical activity on CRC risk. This gene encodes a member of the large gene family that instructs the building of potassium channels and is abundantly expressed in skeletal muscle. \u003cem\u003eKCNG1\u003c/em\u003e has been related to insulin secretion, muscle contraction, and neurotransmitter release regulation, among others [104]; however, its functions are not fully understood. Our findings showed that rs56906466 had statistically significant interactions with physical activity in modifying CRC risk. Furthermore, functional-annotations analyses demonstrated that some of the genetic variants interacting with physical activity were located in enhancers and were linked to differential gene expression. However, additional targeted studies will be necessary to further investigate the joint effects of these genes with physical activity on CRC risk.\u003c/p\u003e\u003cp\u003eThere is increasing evidence that gene-physical activity interactions (including being physically active or inactive) have an effect on several health-related outcomes such as blood pressure, hypertension, BMI, and insulin metabolism [105]. However, few studies have evaluated the gene-physical activity interaction on CRC risk, and all previous studies followed a candidate-gene approach and included only a limited number of SNPs [26\u0026ndash;29]. Two studies evaluated the mediating effects of physical activity on CRC risk via alterations in polymorphisms in the insulin-like growth factor-1 (\u003cem\u003eIGF-1\u003c/em\u003e) gene, since physical activity is known to modulate IGF-1 serum levels, and observed statistically significant interactions [26, 106]. Khoury-Shakour \u003cem\u003eet al\u003c/em\u003e. focused their analysis on the polymorphism rs2665802 at intron 4 of the growth hormone 1 (\u003cem\u003eGH1\u003c/em\u003e) gene and observed that the minor allele A was associated with lower risk of CRC among inactive participants [26]. A recent study assessed the interaction between physical activity and CRC risk based on a polymorphism (rs647161) in the paired-like homeodomain 1 (\u003cem\u003ePITX1\u003c/em\u003e) gene in a Korean population, and reported a higher risk of CRC among participants who exercised less and carried the minor allele [27]. \u003cem\u003ePITX1\u003c/em\u003e is considered a tumor suppressor gene [107], and is known to influence the expression of \u003cem\u003eGH1\u003c/em\u003e, and is related to \u003cem\u003eIGF-1\u003c/em\u003e [108]. Song \u003cem\u003eet al\u003c/em\u003e. assessed interactions between physical activity and 31 SNPs (including rs4779584) on CRC risk among 703 CRC cases and 1,406 healthy controls [28]. However, they observed statistically significant interactions only with rs4444235\u0026ndash;\u0026ndash;with increased CRC risk among C carriers who exercised regularly\u0026ndash;\u0026ndash;but not for rs4779584, which may be due to the small sample size. However, none of the above findings could be replicated in the present study (data not shown). Additionally, we observed no LD-based correlation between rs4779584 and rs4444235 (\u003cem\u003er\u003c/em\u003e\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;=\u0026thinsp;0.004). Given the smaller sample size and candidate gene approach in the study by Song \u003cem\u003eet al\u003c/em\u003e., it is possible that these are chance findings.\u003c/p\u003e\u003cp\u003eA main strength of our study was a large, well-characterized study population, the largest ever to have examined gene-physical activity interactions. The use of several complementary statistical approaches was also a strength of this study as it allowed detection of specific loci within \u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e and near \u003cem\u003eKCNG1\u003c/em\u003e genes. However, our findings may not be generalizable outside of European-descent populations as the participants in this study were limited to those with European descent and were far more active than the US general population. The consortium is actively striving to overcome this limitation by expanding our research to encompass other racial and ethnic groups, as well as by harmonizing epidemiological data, which will enable us to expand our future GxE analyses. Additionally, this study included self-report measures of physical activity which are prone to recall and response biases, but these are likely to attenuate \u0026lsquo;true\u0026rsquo; associations with disease risk [109]. Lastly, our sample size did not allow us to identify genes, whose rare variants may interact with physical activity and contribute to CRC risk in the aggregate test. Additional functional studies are needed to verify the role of the identified SNPs interacting with physical activity for CRC risk.\u003c/p\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eIn conclusion, we identified two novel genetic loci that interact with physical activity to influence CRC risk. Potential mechanisms behind the interaction of rs4779584 and physical activity in CRC risk may be linked in part to the BMP-related, inflammation pathways, and/or insulin signaling in response to physical activity. However, SNP rs56906466 that is near a potassium channel gene, has not been previously described in relation to physical activity or CRC, and additional investigations are required to elucidate the potential mechanisms through which it may be involved in colorectal carcinogenesis, especially in individuals who are not physically active.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthors contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors participated in the revisions to this paper, the interpretation of the results, and approved the final paper. \u003cem\u003eConceptualization\u003c/em\u003e: A.R.P, M.O-S., W.J.G.,U.P., V.M., A.E.K., E.S.K., L.M., Y.L. \u003cem\u003eData curation\u003c/em\u003e: A.E.K., E.S.K., C.Q., F.M-N., J.M., Y.L. Formal analysis: Q.F, A.E.K, E.S.K., C.Q, F.M-N., J.M., Y.L. \u003cem\u003eMethodology\u003c/em\u003e: A.R.P, M.O-S, W.J.G.,U.P., V.M. A.E.K, E.S.K, C.Q, F.M-N., J.M., Y.L. \u003cem\u003eWriting\u0026mdash;original draft\u003c/em\u003e: A.R.P, M.O-S., W.J.G., U.P., V.M., A.E.K., E.S.K., J.M, Y.L. \u003cem\u003eWriting\u0026mdash;Review and editing\u003c/em\u003e: All. \u003cem\u003eSupervision\u003c/em\u003e: U.P., W.J.G., V.M.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCCFR\u003c/em\u003e: The Colon CFR graciously thanks the generous contributions of their study participants, dedication of study staff, and the financial support from the U.S. National Cancer Institute, without which this important registry would not exist. The authors would like to thank the study participants and staff of the Seattle Colon Cancer Family Registry and the Hormones and Colon Cancer study (CORE Studies).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCPS-II\u003c/em\u003e: The authors express sincere appreciation to all Cancer Prevention Study-II participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention\u0026rsquo;s National Program of Cancer Registries and cancer registries supported by the National Cancer Institute\u0026rsquo;s Surveillance Epidemiology and End Results Program. The study protocol was approved by the institutional review boards of Emory University, and those of participating registries as required. The authors assume full responsibility for all analyses and interpretation of results. The views expressed here are those of the authors and do not necessarily represent the American Cancer Society or the American Cancer Society \u0026ndash; Cancer Action Network.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eDACHS\u003c/em\u003e: We thank all participants and cooperating clinicians, and everyone who provided excellent technical assistance.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEPIC\u003c/em\u003e: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHarvard cohorts (HPFS, NHS)\u003c/em\u003e: The study protocol was approved by the institutional review boards of the Brigham and Women\u0026rsquo;s Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention\u0026rsquo;s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute\u0026rsquo;s Surveillance, Epidemiology, and End Results (SEER) Program. \u0026nbsp;Central registries may also be supported by state agencies, universities, and cancer centers. \u0026nbsp;Participating central cancer registries include the following: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kentucky, Louisiana, Massachusetts, Maine, Maryland, Michigan, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Seattle SEER Registry, South Carolina, Tennessee, Texas, Utah, Virginia, West Virginia, Wyoming.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWHI\u003c/em\u003e: The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: https://s3-us-west-2.amazonaws.com/www-whi-org/wp-content/uploads/WHI-Investigator-Long-List.pdf\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eGenetics and Epidemiology of Colorectal Cancer Consortium (GECCO)\u003c/em\u003e: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (U01 CA137088, R01 CA059045, U01 CA164930, R21 CA191312, R01201407, R01CA488857, R01CA273198, R01CA244588). Genotyping/Sequencing services were provided by the Center for Inherited Disease Research (CIDR) contract number HHSN268201700006I and HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685. \u0026nbsp; Statistical methodology and software development at USC funded by P01CA196569.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eColon Cancer Family Registry (CCFR)\u003c/em\u003e: CCFR (www.coloncfr.org) is supported in part by funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The CCFR Set-1 (Illumina 1M/1M-Duo) and Set-2 (Illumina Omni1-Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143247 (to GC). The CCFR Set-3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488 (to SBG). The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported by NIH award U19 CA148107 (to SBG) and by the Center for Inherited Disease Research (CIDR), which is funded by the NIH to the Johns Hopkins University, contract number HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201-043 from the Ontario Research Fund (to BWZ), award 112746 from the Canadian Institutes of Health Research (to TJH), through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society (to SG), and through generous support from the Ontario Ministry of Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to PAN). \u0026nbsp;The content of this manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government, any cancer registry, or the CCFR.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCOLO2\u0026amp;3\u003c/em\u003e: National Institutes of Health (R01 CA060987).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eColorectal Cancer Transdisciplinary (CORECT) Study\u003c/em\u003e: The CORECT Study was supported by the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health and Human Services (grant numbers U19 CA148107, R01 CA81488, P30 CA014089, R01 CA197350; P01 CA196569; R01 CA201407) and National Institutes of Environmental Health Sciences, National Institutes of Health (grant number T32 ES013678).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCPS-II\u003c/em\u003e: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. The study protocol was approved by the institutional review boards of Emory University, and those of participating registries as required.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eDACHS\u003c/em\u003e: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1 and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A and 01ER1505B).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eDALS\u003c/em\u003e: National Institutes of Health (R01 CA48998 to M. L. Slattery).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEDRN\u003c/em\u003e: This work is funded and supported by the NCI, EDRN Grant (U01 CA 84968-06).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEPIC\u003c/em\u003e: The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle G\u0026eacute;n\u0026eacute;rale de l\u0026rsquo;Education Nationale, Institut National de la Sant\u0026eacute; et de la Recherche M\u0026eacute;dicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam- Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andaluc\u0026iacute;a, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Sk\u0026aring;ne and V\u0026auml;sterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHarvard cohorts (HPFS, NHS)\u003c/em\u003e: HPFS is supported by the National Institutes of Health (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35 CA197735), and NHS by the National Institutes of Health (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, and R35 CA197735).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHawaii Adenoma Study\u003c/em\u003e: NCI grants R01 CA072520.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLCCS\u003c/em\u003e: The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and Cancer Research UK Programme Award (C588/A19167).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eMEC\u003c/em\u003e: National Institutes of Health (R37 CA054281, P01 CA033619, and R01 CA063464).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eNCCCS I \u0026amp; II\u003c/em\u003e: We acknowledge funding support for this project from the National Institutes of Health, R01 CA66635 and P30 DK034987.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eNFCCR\u003c/em\u003e: This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821); the National Institutes of Health, U.S. Department of Health and Human Serivces (U01 CA74783); and National Cancer Institute of Canada grants (18223 and 18226). The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and G\u0026eacute;nome Qu\u0026eacute;bec Innovation Centre, Montr\u0026eacute;al, Canada, for genotyping the Sequenom panel in the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society Research Institute.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSwedish Mammography Cohort and Cohort of Swedish Men\u003c/em\u003e: This work is supported by the Swedish Research Council /Infrastructure grant, the Swedish Cancer Foundation, and the Karolinska Institute\u0026acute;s Distinguished Professor Award to Alicja Wolk.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eUK Biobank\u003c/em\u003e: This research has been conducted using the UK Biobank Resource under Application Number 8614.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eVITAL\u003c/em\u003e: National Institutes of Health (K05 CA154337).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWHI\u003c/em\u003e: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001,75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe dataset used in the current study may be available from the corresponding author on reasonable request for researchers who meet the criteria for access to confidential data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was conducted in accordance with the principles of the Declaration of Helsinki, each contributing study was approved by an Institutional Review Board or relevant research committee. For CPS-II, written informed consent was received from participants to obtain medical records. At the time of each mailed survey, participants were informed that their identifying information would be used to link with cancer registries and death indexes. For the other studies, all study participants provided informed consent.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDr. Ulrich has as HCI Cancer Center Director oversight over research funded by several pharmaceutical companies but has not received funding directly herself. Dr. Peters was a consultant with AbbVie and her husband is holding individual stocks for the following companies: BioNTech SE \u0026ndash; ADR, Amazon, CureVac BV, NanoString Technologies, Google/Alphabet Inc\u0026nbsp;Class C, NVIDIA Corp, Microsoft Corp.\u0026nbsp;Other authors declare that they have no conflict of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclaimer\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhere authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: \u003cstrong\u003eGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries\u003c/strong\u003e. \u003cem\u003eCA Cancer J Clin \u003c/em\u003e2021, \u003cstrong\u003e71\u003c/strong\u003e(3):209-249.\u003c/li\u003e\n\u003cli\u003eArnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F: \u003cstrong\u003eGlobal patterns and trends in colorectal cancer incidence and mortality\u003c/strong\u003e. \u003cem\u003eGut \u003c/em\u003e2017, \u003cstrong\u003e66\u003c/strong\u003e(4):683-691.\u003c/li\u003e\n\u003cli\u003eXi Y, Xu P: \u003cstrong\u003eGlobal colorectal cancer burden in 2020 and projections to 2040\u003c/strong\u003e. \u003cem\u003eTransl Oncol \u003c/em\u003e2021, \u003cstrong\u003e14\u003c/strong\u003e(10):101174.\u003c/li\u003e\n\u003cli\u003eSawicki T, Ruszkowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybylowicz KE: \u003cstrong\u003eA Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis\u003c/strong\u003e. \u003cem\u003eCancers (Basel) \u003c/em\u003e2021, \u003cstrong\u003e13\u003c/strong\u003e(9).\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eWorld Cancer Research Fund/American Institute for Cancer Research. Continous Update Project Expert Report 2018. Diet, nutrition, physical activity and colorectal cancer. Available at dietandcancerreport.org\u003c/strong\u003e. In\u003cem\u003e.\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eVan Blarigan EL, Meyerhardt JA: \u003cstrong\u003eRole of physical activity and diet after colorectal cancer diagnosis\u003c/strong\u003e. \u003cem\u003eJ Clin Oncol \u003c/em\u003e2015, \u003cstrong\u003e33\u003c/strong\u003e(16):1825-1834.\u003c/li\u003e\n\u003cli\u003eUlrich CM, Himbert C, Holowatyj AN, Hursting SD: \u003cstrong\u003eEnergy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms\u003c/strong\u003e. \u003cem\u003eNat Rev Gastroenterol Hepatol \u003c/em\u003e2018, \u003cstrong\u003e15\u003c/strong\u003e(11):683-698.\u003c/li\u003e\n\u003cli\u003eLauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K: \u003cstrong\u003eBody Fatness and Cancer--Viewpoint of the IARC Working Group\u003c/strong\u003e. \u003cem\u003eN Engl J Med \u003c/em\u003e2016, \u003cstrong\u003e375\u003c/strong\u003e(8):794-798.\u003c/li\u003e\n\u003cli\u003ePapadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, Kazmi N, Robinson TM, Albanes D, Aleksandrova K\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePhysical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis\u003c/strong\u003e. \u003cem\u003eNat Commun \u003c/em\u003e2020, \u003cstrong\u003e11\u003c/strong\u003e(1):597.\u003c/li\u003e\n\u003cli\u003eKyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePhysical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013\u003c/strong\u003e. \u003cem\u003eBMJ \u003c/em\u003e2016, \u003cstrong\u003e354\u003c/strong\u003e:i3857.\u003c/li\u003e\n\u003cli\u003eMatthews CE, Moore SC, Arem H, Cook MB, Trabert B, Hakansson N, Larsson SC, Wolk A, Gapstur SM, Lynch BM\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eAmount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk\u003c/strong\u003e. \u003cem\u003eJ Clin Oncol \u003c/em\u003e2020, \u003cstrong\u003e38\u003c/strong\u003e(7):686-697.\u003c/li\u003e\n\u003cli\u003eMcTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePhysical Activity in Cancer Prevention and Survival: A Systematic Review\u003c/strong\u003e. \u003cem\u003eMed Sci Sports Exerc \u003c/em\u003e2019, \u003cstrong\u003e51\u003c/strong\u003e(6):1252-1261.\u003c/li\u003e\n\u003cli\u003eMorris JS, Bradbury KE, Cross AJ, Gunter MJ, Murphy N: \u003cstrong\u003ePhysical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank\u003c/strong\u003e. \u003cem\u003eBr J Cancer \u003c/em\u003e2018, \u003cstrong\u003e118\u003c/strong\u003e(6):920-929.\u003c/li\u003e\n\u003cli\u003eGuthold R, Stevens GA, Riley LM, Bull FC: \u003cstrong\u003eWorldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants\u003c/strong\u003e. \u003cem\u003eLancet Glob Health \u003c/em\u003e2018, \u003cstrong\u003e6\u003c/strong\u003e(10):e1077-e1086.\u003c/li\u003e\n\u003cli\u003eMorley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS: \u003cstrong\u003eSarcopenia\u003c/strong\u003e. \u003cem\u003eJ Lab Clin Med \u003c/em\u003e2001, \u003cstrong\u003e137\u003c/strong\u003e(4):231-243.\u003c/li\u003e\n\u003cli\u003eKruijsen-Jaarsma M, Revesz D, Bierings MB, Buffart LM, Takken T: \u003cstrong\u003eEffects of exercise on immune function in patients with cancer: a systematic review\u003c/strong\u003e. \u003cem\u003eExerc Immunol Rev \u003c/em\u003e2013, \u003cstrong\u003e19\u003c/strong\u003e:120-143.\u003c/li\u003e\n\u003cli\u003eSitlinger A, Brander DM, Bartlett DB: \u003cstrong\u003eImpact of exercise on the immune system and outcomes in hematologic malignancies\u003c/strong\u003e. \u003cem\u003eBlood Adv \u003c/em\u003e2020, \u003cstrong\u003e4\u003c/strong\u003e(8):1801-1811.\u003c/li\u003e\n\u003cli\u003eCraft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS: \u003cstrong\u003eExercise effects on depressive symptoms in cancer survivors: a systematic review and meta-analysis\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2012, \u003cstrong\u003e21\u003c/strong\u003e(1):3-19.\u003c/li\u003e\n\u003cli\u003eBrown JC, Huedo-Medina TB, Pescatello LS, Ryan SM, Pescatello SM, Moker E, LaCroix JM, Ferrer RA, Johnson BT: \u003cstrong\u003eThe efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis\u003c/strong\u003e. \u003cem\u003ePLoS One \u003c/em\u003e2012, \u003cstrong\u003e7\u003c/strong\u003e(1):e30955.\u003c/li\u003e\n\u003cli\u003eKredlow MA, Capozzoli MC, Hearon BA, Calkins AW, Otto MW: \u003cstrong\u003eThe effects of physical activity on sleep: a meta-analytic review\u003c/strong\u003e. \u003cem\u003eJ Behav Med \u003c/em\u003e2015, \u003cstrong\u003e38\u003c/strong\u003e(3):427-449.\u003c/li\u003e\n\u003cli\u003eTakemura N, Cheung DST, Smith R, Deng W, Ho KY, Lin J, Kwok JYY, Lam TC, Lin CC: \u003cstrong\u003eEffectiveness of aerobic exercise and mind-body exercise in cancer patients with poor sleep quality: A systematic review and meta-analysis of randomized controlled trials\u003c/strong\u003e. \u003cem\u003eSleep Med Rev \u003c/em\u003e2020, \u003cstrong\u003e53\u003c/strong\u003e:101334.\u003c/li\u003e\n\u003cli\u003eMurphy N, Cross AJ, Abubakar M, Jenab M, Aleksandrova K, Boutron-Ruault MC, Dossus L, Racine A, Kuhn T, Katzke VA\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eA Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)\u003c/strong\u003e. \u003cem\u003ePLoS Med \u003c/em\u003e2016, \u003cstrong\u003e13\u003c/strong\u003e(4):e1001988.\u003c/li\u003e\n\u003cli\u003eHo GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski RT\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eAdipokines linking obesity with colorectal cancer risk in postmenopausal women\u003c/strong\u003e. \u003cem\u003eCancer Res \u003c/em\u003e2012, \u003cstrong\u003e72\u003c/strong\u003e(12):3029-3037.\u003c/li\u003e\n\u003cli\u003eZhou B, Shu B, Yang J, Liu J, Xi T, Xing Y: \u003cstrong\u003eC-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis\u003c/strong\u003e. \u003cem\u003eCancer Causes Control \u003c/em\u003e2014, \u003cstrong\u003e25\u003c/strong\u003e(10):1397-1405.\u003c/li\u003e\n\u003cli\u003eHimbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eDifferences in the gut microbiome by physical activity and BMI among colorectal cancer patients\u003c/strong\u003e. \u003cem\u003eAm J Cancer Res \u003c/em\u003e2022, \u003cstrong\u003e12\u003c/strong\u003e(10):4789-4801.\u003c/li\u003e\n\u003cli\u003eKhoury-Shakour S, Gruber SB, Lejbkowicz F, Rennert HS, Raskin L, Pinchev M, Rennert G: \u003cstrong\u003eRecreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2008, \u003cstrong\u003e17\u003c/strong\u003e(12):3314-3318.\u003c/li\u003e\n\u003cli\u003eGunathilake MN, Lee J, Cho YA, Oh JH, Chang HJ, Sohn DK, Shin A, Kim J: \u003cstrong\u003eInteraction between physical activity, PITX1 rs647161 genetic polymorphism and colorectal cancer risk in a Korean population: a case-control study\u003c/strong\u003e. \u003cem\u003eOncotarget \u003c/em\u003e2018, \u003cstrong\u003e9\u003c/strong\u003e(7):7590-7603.\u003c/li\u003e\n\u003cli\u003eSong N, Lee J, Cho S, Kim J, Oh JH, Shin A: \u003cstrong\u003eEvaluation of gene-environment interactions for colorectal cancer susceptibility loci using case-only and case-control designs\u003c/strong\u003e. \u003cem\u003eBMC Cancer \u003c/em\u003e2019, \u003cstrong\u003e19\u003c/strong\u003e(1):1231.\u003c/li\u003e\n\u003cli\u003eMorimoto LM, Newcomb PA, White E, Bigler J, Potter JD: \u003cstrong\u003eInsulin-like growth factor polymorphisms and colorectal cancer risk\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2005, \u003cstrong\u003e14\u003c/strong\u003e(5):1204-1211.\u003c/li\u003e\n\u003cli\u003eHuyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eDiscovery of common and rare genetic risk variants for colorectal cancer\u003c/strong\u003e. \u003cem\u003eNat Genet \u003c/em\u003e2019, \u003cstrong\u003e51\u003c/strong\u003e(1):76-87.\u003c/li\u003e\n\u003cli\u003ePeters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eIdentification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis\u003c/strong\u003e. \u003cem\u003eGastroenterology \u003c/em\u003e2013, \u003cstrong\u003e144\u003c/strong\u003e(4):799-807 e724.\u003c/li\u003e\n\u003cli\u003eSchmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eNovel Common Genetic Susceptibility Loci for Colorectal Cancer\u003c/strong\u003e. \u003cem\u003eJ Natl Cancer Inst \u003c/em\u003e2019, \u003cstrong\u003e111\u003c/strong\u003e(2):146-157.\u003c/li\u003e\n\u003cli\u003eSchumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, Hsu L, Huang SC, Fischer CP, Harju JF\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGenome-wide association study of colorectal cancer identifies six new susceptibility loci\u003c/strong\u003e. \u003cem\u003eNat Commun \u003c/em\u003e2015, \u003cstrong\u003e6\u003c/strong\u003e:7138.\u003c/li\u003e\n\u003cli\u003eHutter CM, Chang-Claude J, Slattery ML, Pflugeisen BM, Lin Y, Duggan D, Nan H, Lemire M, Rangrej J, Figueiredo JC\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eCharacterization of gene-environment interactions for colorectal cancer susceptibility loci\u003c/strong\u003e. \u003cem\u003eCancer Res \u003c/em\u003e2012, \u003cstrong\u003e72\u003c/strong\u003e(8):2036-2044.\u003c/li\u003e\n\u003cli\u003ePeters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eIdentification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis\u003c/strong\u003e. \u003cem\u003eGastroenterology \u003c/em\u003e2013, \u003cstrong\u003e144\u003c/strong\u003e(4):799-807.e724.\u003c/li\u003e\n\u003cli\u003eRolland B, Reid S, Stelling D, Warnick G, Thornquist M, Feng Z, Potter JD: \u003cstrong\u003eToward Rigorous Data Harmonization in Cancer Epidemiology Research: One Approach\u003c/strong\u003e. \u003cem\u003eAm J Epidemiol \u003c/em\u003e2015, \u003cstrong\u003e182\u003c/strong\u003e(12):1033-1038.\u003c/li\u003e\n\u003cli\u003eLittman AJ, White E, Kristal AR, Patterson RE, Satia-Abouta J, Potter JD: \u003cstrong\u003eAssessment of a one-page questionnaire on long-term recreational physical activity\u003c/strong\u003e. \u003cem\u003eEpidemiology \u003c/em\u003e2004, \u003cstrong\u003e15\u003c/strong\u003e(1):105-113.\u003c/li\u003e\n\u003cli\u003eNelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C: \u003cstrong\u003ePhysical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association\u003c/strong\u003e. \u003cem\u003eMed Sci Sports Exerc \u003c/em\u003e2007, \u003cstrong\u003e39\u003c/strong\u003e(8):1435-1445.\u003c/li\u003e\n\u003cli\u003ePiercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, George SM, Olson RD: \u003cstrong\u003eThe Physical Activity Guidelines for Americans\u003c/strong\u003e. \u003cem\u003eJama \u003c/em\u003e2018, \u003cstrong\u003e320\u003c/strong\u003e(19):2020-2028.\u003c/li\u003e\n\u003cli\u003eSchmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eAmerican College of Sports Medicine roundtable on exercise guidelines for cancer survivors\u003c/strong\u003e. \u003cem\u003eMed Sci Sports Exerc \u003c/em\u003e2010, \u003cstrong\u003e42\u003c/strong\u003e(7):1409-1426.\u003c/li\u003e\n\u003cli\u003eKushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eAmerican Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity\u003c/strong\u003e. \u003cem\u003eCA Cancer J Clin \u003c/em\u003e2012, \u003cstrong\u003e62\u003c/strong\u003e(1):30-67.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eWHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003ePhipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003ePhysical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance)\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2018, \u003cstrong\u003e27\u003c/strong\u003e(6):696-703.\u003c/li\u003e\n\u003cli\u003eHardikar S, Newcomb PA, Campbell PT, Win AK, Lindor NM, Buchanan DD, Makar KW, Jenkins MA, Potter JD, Phipps AI: \u003cstrong\u003ePrediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2015, \u003cstrong\u003e24\u003c/strong\u003e(7):1130-1137.\u003c/li\u003e\n\u003cli\u003eKuiper JG, Phipps AI, Neuhouser ML, Chlebowski RT, Thomson CA, Irwin ML, Lane DS, Wactawski-Wende J, Hou L, Jackson RD\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eRecreational physical activity, body mass index, and survival in women with colorectal cancer\u003c/strong\u003e. \u003cem\u003eCancer Causes Control \u003c/em\u003e2012, \u003cstrong\u003e23\u003c/strong\u003e(12):1939-1948.\u003c/li\u003e\n\u003cli\u003eDas S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy S, McGue M\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eNext-generation genotype imputation service and methods\u003c/strong\u003e. \u003cem\u003eNat Genet \u003c/em\u003e2016, \u003cstrong\u003e48\u003c/strong\u003e(10):1284-1287.\u003c/li\u003e\n\u003cli\u003eMorrison J: \u003cstrong\u003ehttps://cran.r-project.org/package=BinaryDosage\u003c/strong\u003e. 2020.\u003c/li\u003e\n\u003cli\u003eAbecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA: \u003cstrong\u003eAn integrated map of genetic variation from 1,092 human genomes\u003c/strong\u003e. \u003cem\u003eNature \u003c/em\u003e2012, \u003cstrong\u003e491\u003c/strong\u003e(7422):56-65.\u003c/li\u003e\n\u003cli\u003eIntHout J, Ioannidis JP, Borm GF: \u003cstrong\u003eThe Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method\u003c/strong\u003e. \u003cem\u003eBMC Med Res Methodol \u003c/em\u003e2014, \u003cstrong\u003e14\u003c/strong\u003e:25.\u003c/li\u003e\n\u003cli\u003eCochran WG: \u003cstrong\u003eThe combination of estimates from different experiments\u003c/strong\u003e. 1954, \u003cstrong\u003e10\u003c/strong\u003e:101-129.\u003c/li\u003e\n\u003cli\u003eGuido Schwarzer JRC, Gerta R\u0026uuml;cker.: \u003cstrong\u003eMeta-Analysis with R\u003c/strong\u003e. Switzerland: Springer, Cham; 2015.\u003c/li\u003e\n\u003cli\u003eDai JY, Logsdon BA, Huang Y, Hsu L, Reiner AP, Prentice RL, Kooperberg C: \u003cstrong\u003eSimultaneously testing for marginal genetic association and gene-environment interaction\u003c/strong\u003e. \u003cem\u003eAm J Epidemiol \u003c/em\u003e2012, \u003cstrong\u003e176\u003c/strong\u003e(2):164-173.\u003c/li\u003e\n\u003cli\u003eGauderman WJ, Kim A, Conti DV, Morrison J, Thomas DC, Vora H, Lewinger JP: \u003cstrong\u003eA Unified Model for the Analysis of Gene-Environment Interaction\u003c/strong\u003e. \u003cem\u003eAmerican journal of epidemiology \u003c/em\u003e2019, \u003cstrong\u003e188\u003c/strong\u003e(4):760-767.\u003c/li\u003e\n\u003cli\u003eGao X, Starmer J, Martin ER: \u003cstrong\u003eA multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms\u003c/strong\u003e. \u003cem\u003eGenet Epidemiol \u003c/em\u003e2008, \u003cstrong\u003e32\u003c/strong\u003e(4):361-369.\u003c/li\u003e\n\u003cli\u003eKawaguchi ES, Kim AE, Lewinger JP, Gauderman WJ: \u003cstrong\u003eImproved two-step testing of genome-wide gene-environment interactions\u003c/strong\u003e. \u003cem\u003ebioRxiv \u003c/em\u003e2022:2022.2006.2014.496154.\u003c/li\u003e\n\u003cli\u003eGauderman WJ, Zhang P, Morrison JL, Lewinger JP: \u003cstrong\u003eFinding novel genes by testing G \u0026times; E interactions in a genome-wide association study\u003c/strong\u003e. \u003cem\u003eGenet Epidemiol \u003c/em\u003e2013, \u003cstrong\u003e37\u003c/strong\u003e(6):603-613.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eMorrison JL, Gauderman WJ (2020). GxEScanR: Run GWAS/GWEIS Scans Using Binary Dosage Files. R package version 2.0.2. \u003c/strong\u003e\u003cstrong\u003ehttps://CRAN.R-project.org/package=GxEScanR\u003c/strong\u003e.\u003c/li\u003e\n\u003cli\u003eKraft P, Yen YC, Stram DO, Morrison J, Gauderman WJ: \u003cstrong\u003eExploiting gene-environment interaction to detect genetic associations\u003c/strong\u003e. \u003cem\u003eHum Hered \u003c/em\u003e2007, \u003cstrong\u003e63\u003c/strong\u003e(2):111-119.\u003c/li\u003e\n\u003cli\u003eMurcray CE, Lewinger JP, Gauderman WJ: \u003cstrong\u003eGene-environment interaction in genome-wide association studies\u003c/strong\u003e. \u003cem\u003eAm J Epidemiol \u003c/em\u003e2009, \u003cstrong\u003e169\u003c/strong\u003e(2):219-226.\u003c/li\u003e\n\u003cli\u003eKooperberg C, Leblanc M: \u003cstrong\u003eIncreasing the power of identifying gene x gene interactions in genome-wide association studies\u003c/strong\u003e. \u003cem\u003eGenetic epidemiology \u003c/em\u003e2008, \u003cstrong\u003e32\u003c/strong\u003e(3):255-263.\u003c/li\u003e\n\u003cli\u003eIonita-Laza I, McQueen MB, Laird NM, Lange C: \u003cstrong\u003eGenomewide weighted hypothesis testing in family-based association studies, with an application to a 100K scan\u003c/strong\u003e. \u003cem\u003eAmerican journal of human genetics \u003c/em\u003e2007, \u003cstrong\u003e81\u003c/strong\u003e(3):607-614.\u003c/li\u003e\n\u003cli\u003eLewinger JP, Kawaguchi ES, Gauderman WJ: \u003cstrong\u003eA note on p-value multiple-testing adjustment for two-step genome-wide gene-environment interactions scans\u003c/strong\u003e. \u003cem\u003emedRxiv \u003c/em\u003e2023.\u003c/li\u003e\n\u003cli\u003ede Bakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, Voight BF: \u003cstrong\u003ePractical aspects of imputation-driven meta-analysis of genome-wide association studies\u003c/strong\u003e. \u003cem\u003eHum Mol Genet \u003c/em\u003e2008, \u003cstrong\u003e17\u003c/strong\u003e(R2):R122-128.\u003c/li\u003e\n\u003cli\u003eDevlin B, Roeder K: \u003cstrong\u003eGenomic control for association studies\u003c/strong\u003e. \u003cem\u003eBiometrics \u003c/em\u003e1999, \u003cstrong\u003e55\u003c/strong\u003e(4):997-1004.\u003c/li\u003e\n\u003cli\u003eSun M, Bjorge T, Teleka S, Engeland A, Wennberg P, Haggstrom C, Stocks T: \u003cstrong\u003eInteraction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study\u003c/strong\u003e. \u003cem\u003eInt J Cancer \u003c/em\u003e2022, \u003cstrong\u003e151\u003c/strong\u003e(6):859-868.\u003c/li\u003e\n\u003cli\u003ePruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer CJ: \u003cstrong\u003eLocusZoom: regional visualization of genome-wide association scan results\u003c/strong\u003e. \u003cem\u003eBioinformatics \u003c/em\u003e2010, \u003cstrong\u003e26\u003c/strong\u003e(18):2336-2337.\u003c/li\u003e\n\u003cli\u003eDiez-Obrero V, Dampier CH, Moratalla-Navarro F, Devall M, Plummer SJ, Diez-Villanueva A, Peters U, Bien S, Huyghe JR, Kundaje A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGenetic Effects on Transcriptome Profiles in Colon Epithelium Provide Functional Insights for Genetic Risk Loci\u003c/strong\u003e. \u003cem\u003eCell Mol Gastroenterol Hepatol \u003c/em\u003e2021, \u003cstrong\u003e12\u003c/strong\u003e(1):181-197.\u003c/li\u003e\n\u003cli\u003eJordahl KM, Shcherbina A, Kim AE, Su YR, Lin Y, Wang J, Qu C, Albanes D, Arndt V, Baurley JW\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eBeyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region\u003c/strong\u003e. \u003cem\u003eCancer epidemiology, biomarkers \u0026amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology \u003c/em\u003e2022, \u003cstrong\u003e31\u003c/strong\u003e(5):1077-1089.\u003c/li\u003e\n\u003cli\u003eTian Y, Kim AE, Bien SA, Lin Y, Qu C, Harrison T, Carreras-Torres R, Diez-Obrero V, Dimou N, Drew DA\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGenome-Wide Interaction Analysis of Genetic Variants with Menopausal Hormone Therapy for Colorectal Cancer Risk\u003c/strong\u003e. \u003cem\u003eJ Natl Cancer Inst \u003c/em\u003e2022.\u003c/li\u003e\n\u003cli\u003eCohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eHotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome\u003c/strong\u003e. \u003cem\u003eNat Commun \u003c/em\u003e2017, \u003cstrong\u003e8\u003c/strong\u003e:14400.\u003c/li\u003e\n\u003cli\u003eLee J, Jolanki O, Kim D, Strattan JS, Kundaje A, Nordstr\u0026ouml;m K, Shcherbina A: \u003cstrong\u003eENCODE-DCC/atac-seq-pipeline: v1.9.1\u003c/strong\u003e. 2020.\u003c/li\u003e\n\u003cli\u003eLee J, Strattan JS, Shcherbina A, Kagda M, Maurizio PL: \u003cstrong\u003eENCODE-DCC/chip-seq-pipeline2: v1.6.1\u003c/strong\u003e. 2020.\u003c/li\u003e\n\u003cli\u003eSu YR, Di CZ, Hsu L, Genetics, Epidemiology of Colorectal Cancer C: \u003cstrong\u003eA unified powerful set-based test for sequencing data analysis of GxE interactions\u003c/strong\u003e. \u003cem\u003eBiostatistics \u003c/em\u003e2017, \u003cstrong\u003e18\u003c/strong\u003e(1):119-131.\u003c/li\u003e\n\u003cli\u003eTu L, Yan B, Peng Z: \u003cstrong\u003eCommon genetic variants (rs4779584 and rs10318) at 15q13.3 contributes to colorectal adenoma and colorectal cancer susceptibility: evidence based on 22 studies\u003c/strong\u003e. \u003cem\u003eMol Genet Genomics \u003c/em\u003e2015, \u003cstrong\u003e290\u003c/strong\u003e(3):901-912.\u003c/li\u003e\n\u003cli\u003eYang H, Gao Y, Feng T, Jin TB, Kang LL, Chen C: \u003cstrong\u003eMeta-analysis of the rs4779584 polymorphism and colorectal cancer risk\u003c/strong\u003e. \u003cem\u003ePLoS One \u003c/em\u003e2014, \u003cstrong\u003e9\u003c/strong\u003e(2):e89736.\u003c/li\u003e\n\u003cli\u003ePeters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, Edlund CK, Haile RW, Gallinger S, Zanke BW\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eMeta-analysis of new genome-wide association studies of colorectal cancer risk\u003c/strong\u003e. \u003cem\u003eHum Genet \u003c/em\u003e2012, \u003cstrong\u003e131\u003c/strong\u003e(2):217-234.\u003c/li\u003e\n\u003cli\u003eWhiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, Lloyd A, Kinnersley B, Gorman M, Tenesa A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eIdentification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis\u003c/strong\u003e. \u003cem\u003eHum Mol Genet \u003c/em\u003e2014, \u003cstrong\u003e23\u003c/strong\u003e(17):4729-4737.\u003c/li\u003e\n\u003cli\u003eTanskanen T, van den Berg L, Valimaki N, Aavikko M, Ness-Jensen E, Hveem K, Wettergren Y, Bexe Lindskog E, Tonisson N, Metspalu A\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGenome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci\u003c/strong\u003e. \u003cem\u003eInt J Cancer \u003c/em\u003e2018, \u003cstrong\u003e142\u003c/strong\u003e(3):540-546.\u003c/li\u003e\n\u003cli\u003eRakshit S, Bhaskar LVKS: \u003cstrong\u003eAn Intergenic Variant rs4779584 Between SCG5 and GREM1 Contributes to the Increased Risk of Colorectal Cancer: A Meta-Analysis\u003c/strong\u003e. In: \u003cem\u003eNovel therapeutic approaches for gastrointestinal malignancies Diagnostics and Therapeutic Advances in GI Malignancies.\u003c/em\u003e edn. Edited by Nagaraju GP, Peela S. Singapore: Springer; 2020: 159-169.\u003c/li\u003e\n\u003cli\u003eJaeger E, Webb E, Howarth K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittman A, Kemp Z\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eCommon genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk\u003c/strong\u003e. \u003cem\u003eNat Genet \u003c/em\u003e2008, \u003cstrong\u003e40\u003c/strong\u003e(1):26-28.\u003c/li\u003e\n\u003cli\u003eDerynck R, Akhurst RJ, Balmain A: \u003cstrong\u003eTGF-beta signaling in tumor suppression and cancer progression\u003c/strong\u003e. \u003cem\u003eNat Genet \u003c/em\u003e2001, \u003cstrong\u003e29\u003c/strong\u003e(2):117-129.\u003c/li\u003e\n\u003cli\u003eStabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eBone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor\u003c/strong\u003e. \u003cem\u003eBlood \u003c/em\u003e2007, \u003cstrong\u003e109\u003c/strong\u003e(5):1834-1840.\u003c/li\u003e\n\u003cli\u003eHedjazifar S, Khatib Shahidi R, Hammarstedt A, Bonnet L, Church C, Boucher J, Bluher M, Smith U: \u003cstrong\u003eThe Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH\u003c/strong\u003e. \u003cem\u003eDiabetes \u003c/em\u003e2020, \u003cstrong\u003e69\u003c/strong\u003e(3):331-341.\u003c/li\u003e\n\u003cli\u003eKobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, Lida T, Ando R, Suzuki N, Lannagan TRM\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eThe Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis\u003c/strong\u003e. \u003cem\u003eGastroenterology \u003c/em\u003e2021, \u003cstrong\u003e160\u003c/strong\u003e(4):1224-1239 e1230.\u003c/li\u003e\n\u003cli\u003eRen J, Smid M, Iaria J, Salvatori DCF, van Dam H, Zhu HJ, Martens JWM, Ten Dijke P: \u003cstrong\u003eCancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression\u003c/strong\u003e. \u003cem\u003eBreast Cancer Res \u003c/em\u003e2019, \u003cstrong\u003e21\u003c/strong\u003e(1):109.\u003c/li\u003e\n\u003cli\u003eCorsini M, Moroni E, Ravelli C, Andres G, Grillo E, Ali IH, Brazil DP, Presta M, Mitola S: \u003cstrong\u003eCyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin\u003c/strong\u003e. \u003cem\u003eArterioscler Thromb Vasc Biol \u003c/em\u003e2014, \u003cstrong\u003e34\u003c/strong\u003e(1):136-145.\u003c/li\u003e\n\u003cli\u003eSeidah NG, Chretien M: \u003cstrong\u003eProprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides\u003c/strong\u003e. \u003cem\u003eBrain Res \u003c/em\u003e1999, \u003cstrong\u003e848\u003c/strong\u003e(1-2):45-62.\u003c/li\u003e\n\u003cli\u003eMbikay M, Seidah NG, Chretien M: \u003cstrong\u003eNeuroendocrine secretory protein 7B2: structure, expression and functions\u003c/strong\u003e. \u003cem\u003eBiochem J \u003c/em\u003e2001, \u003cstrong\u003e357\u003c/strong\u003e(Pt 2):329-342.\u003c/li\u003e\n\u003cli\u003eZiai J, Matloff E, Choi J, Kombo N, Materin M, Bale AE: \u003cstrong\u003eDefining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: counselling and management recommendations\u003c/strong\u003e. \u003cem\u003eGenet Res (Camb) \u003c/em\u003e2016, \u003cstrong\u003e98\u003c/strong\u003e:e5.\u003c/li\u003e\n\u003cli\u003eYusuf I, Pardamean B, Baurley JW, Budiarto A, Miskad UA, Lusikooy RE, Arsyad A, Irwan A, Mathew G, Suriapranata I\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGenetic risk factors for colorectal cancer in multiethnic Indonesians\u003c/strong\u003e. \u003cem\u003eSci Rep \u003c/em\u003e2021, \u003cstrong\u003e11\u003c/strong\u003e(1):9988.\u003c/li\u003e\n\u003cli\u003eJo Y, Yeo MK, Dao T, Kwon J, Yi HS, Ryu D: \u003cstrong\u003eMachine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia\u003c/strong\u003e. \u003cem\u003eFront Oncol \u003c/em\u003e2022, \u003cstrong\u003e12\u003c/strong\u003e:942774.\u003c/li\u003e\n\u003cli\u003eFarber CR, Chitwood J, Lee SN, Verdugo RA, Islas-Trejo A, Rincon G, Lindberg I, Medrano JF: \u003cstrong\u003eOverexpression of Scg5 increases enzymatic activity of PCSK2 and is inversely correlated with body weight in congenic mice\u003c/strong\u003e. \u003cem\u003eBMC Genet \u003c/em\u003e2008, \u003cstrong\u003e9\u003c/strong\u003e:34.\u003c/li\u003e\n\u003cli\u003eKlimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, Alexander GE, Chen Z, Going SB: \u003cstrong\u003eGenome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE\u003c/strong\u003e. \u003cem\u003eInt J Obes (Lond) \u003c/em\u003e2018, \u003cstrong\u003e42\u003c/strong\u003e(6):1161-1176.\u003c/li\u003e\n\u003cli\u003eDoherty A, Smith-Byrne K, Ferreira T, Holmes MV, Holmes C, Pulit SL, Lindgren CM: \u003cstrong\u003eGWAS identifies 14 loci for device-measured physical activity and sleep duration\u003c/strong\u003e. \u003cem\u003eNat Commun \u003c/em\u003e2018, \u003cstrong\u003e9\u003c/strong\u003e(1):5257.\u003c/li\u003e\n\u003cli\u003eFabre O, Giordani L, Parisi A, Pattamaprapanont P, Ahwazi D, Brun C, Chakroun I, Taleb A, Blais A, Andersen E\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eGREM1 is epigenetically reprogrammed in muscle cells after exercise training and controls myogenesis and metabolism\u003c/strong\u003e. \u003cem\u003ebioRxiv \u003c/em\u003e2020:2020.2002.2020.956300.\u003c/li\u003e\n\u003cli\u003eJurdana M: \u003cstrong\u003ePhysical activity and cancer risk. Actual knowledge and possible biological mechanisms\u003c/strong\u003e. \u003cem\u003eRadiol Oncol \u003c/em\u003e2021, \u003cstrong\u003e55\u003c/strong\u003e(1):7-17.\u003c/li\u003e\n\u003cli\u003eWang T, Zhang Y, Taaffe DR, Kim JS, Luo H, Yang L, Fairman CM, Qiao Y, Newton RU, Galvao DA: \u003cstrong\u003eProtective effects of physical activity in colon cancer and underlying mechanisms: A review of epidemiological and biological evidence\u003c/strong\u003e. \u003cem\u003eCrit Rev Oncol Hematol \u003c/em\u003e2022, \u003cstrong\u003e170\u003c/strong\u003e:103578.\u003c/li\u003e\n\u003cli\u003eDziewiecka H, Buttar HS, Kasperska A, Ostapiuk-Karolczuk J, Domagalska M, Cichon J, Skarpanska-Stejnborn A: \u003cstrong\u003ePhysical activity induced alterations of gut microbiota in humans: a systematic review\u003c/strong\u003e. \u003cem\u003eBMC Sports Sci Med Rehabil \u003c/em\u003e2022, \u003cstrong\u003e14\u003c/strong\u003e(1):122.\u003c/li\u003e\n\u003cli\u003eSaeidi A, Seifi-Ski-Shahr F, Soltani M, Daraei A, Shirvani H, Laher I, Hackney AC, Johnson KE, Basati G, Zouhal H: \u003cstrong\u003eResistance training, gremlin 1 and macrophage migration inhibitory factor in obese men: a randomised trial\u003c/strong\u003e. \u003cem\u003eArch Physiol Biochem \u003c/em\u003e2020:1-9.\u003c/li\u003e\n\u003cli\u003eAtaeinosrat A, Saeidi A, Abednatanzi H, Rahmani H, Daloii AA, Pashaei Z, Hojati V, Basati G, Mossayebi A, Laher I\u003cem\u003e et al\u003c/em\u003e: \u003cstrong\u003eIntensity Dependent Effects of Interval Resistance Training on Myokines and Cardiovascular Risk Factors in Males With Obesity\u003c/strong\u003e. \u003cem\u003eFront Endocrinol (Lausanne) \u003c/em\u003e2022, \u003cstrong\u003e13\u003c/strong\u003e:895512.\u003c/li\u003e\n\u003cli\u003ePourteymour S, Eckardt K, Holen T, Langleite T, Lee S, Jensen J, Birkeland KI, Drevon CA, Hjorth M: \u003cstrong\u003eGlobal mRNA sequencing of human skeletal muscle: Search for novel exercise-regulated myokines\u003c/strong\u003e. \u003cem\u003eMol Metab \u003c/em\u003e2017, \u003cstrong\u003e6\u003c/strong\u003e(4):352-365.\u003c/li\u003e\n\u003cli\u003eSaran U, Guarino M, Rodriguez S, Simillion C, Montani M, Foti M, Humar B, St-Pierre MV, Dufour JF: \u003cstrong\u003eAnti-tumoral effects of exercise on hepatocellular carcinoma growth\u003c/strong\u003e. \u003cem\u003eHepatol Commun \u003c/em\u003e2018, \u003cstrong\u003e2\u003c/strong\u003e(5):607-620.\u003c/li\u003e\n\u003cli\u003eEndo Y, Zhang Y, Olumi S, Karvar M, Argawal S, Neppl RL, Sinha I: \u003cstrong\u003eExercise-induced gene expression changes in skeletal muscle of old mice\u003c/strong\u003e. \u003cem\u003eGenomics \u003c/em\u003e2021, \u003cstrong\u003e113\u003c/strong\u003e(5):2965-2976.\u003c/li\u003e\n\u003cli\u003e\u003cstrong\u003eEntrez Gene: KCNG1 potassium voltage-gated channel, subfamily G, member 1. Available at \u003c/strong\u003e\u003cstrong\u003ehttps://www.ncbi.nlm.nih.gov/gene/3755\u003c/strong\u003e. In\u003cem\u003e.\u003c/em\u003e\u003c/li\u003e\n\u003cli\u003eBray MS, Hagberg JM, Perusse L, Rankinen T, Roth SM, Wolfarth B, Bouchard C: \u003cstrong\u003eThe human gene map for performance and health-related fitness phenotypes: the 2006-2007 update\u003c/strong\u003e. \u003cem\u003eMed Sci Sports Exerc \u003c/em\u003e2009, \u003cstrong\u003e41\u003c/strong\u003e(1):35-73.\u003c/li\u003e\n\u003cli\u003eWong HL, Koh WP, Probst-Hensch NM, Van den Berg D, Yu MC, Ingles SA: \u003cstrong\u003eInsulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach\u003c/strong\u003e. \u003cem\u003eGut \u003c/em\u003e2008, \u003cstrong\u003e57\u003c/strong\u003e(8):1090-1096.\u003c/li\u003e\n\u003cli\u003eKe J, Lou J, Chen X, Li J, Liu C, Gong Y, Yang Y, Zhu Y, Zhang Y, Gong J: \u003cstrong\u003eIdentification of a Potential Regulatory Variant for Colorectal Cancer Risk Mapping to Chromosome 5q31.1: A Post-GWAS Study\u003c/strong\u003e. \u003cem\u003ePLoS One \u003c/em\u003e2015, \u003cstrong\u003e10\u003c/strong\u003e(9):e0138478.\u003c/li\u003e\n\u003cli\u003eLiu DX, Lobie PE: \u003cstrong\u003eTranscriptional activation of p53 by Pitx1\u003c/strong\u003e. \u003cem\u003eCell Death Differ \u003c/em\u003e2007, \u003cstrong\u003e14\u003c/strong\u003e(11):1893-1907.\u003c/li\u003e\n\u003cli\u003ePrince SA, Adamo KB, Hamel ME, Hardt J, Connor Gorber S, Tremblay M: \u003cstrong\u003eA comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review\u003c/strong\u003e. \u003cem\u003eInt J Behav Nutr Phys Act \u003c/em\u003e2008, \u003cstrong\u003e5\u003c/strong\u003e:56.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmed","sideBox":"Learn more about [BMC Medicine](http://bmcmedicine.biomedcentral.com/)","snPcode":"12916","submissionUrl":"https://submission.nature.com/new-submission/12916/3","title":"BMC Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"physical activity, gene-environment interaction, colorectal cancer, GWAS","lastPublishedDoi":"10.21203/rs.3.rs-7350654/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7350654/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003ePhysical activity (PA) is an established protective factor for colorectal cancer (CRC), but it is unclear if genetic variants modify this effect. To investigate this possibility, we conducted a genome-wide gene\u0026ndash;PA interaction analysis.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eUsing logistic regression and two-step and joint tests, we analyzed interactions between common genetic variants across the genome and PA in relation to CRC risk. Self-reported PA levels were categorized as active (\u0026ge;\u0026thinsp;8.75 MET-h/wk) vs. inactive (\u0026lt;\u0026thinsp;8.75 MET-h/wk) and as study- and sex-specific quartiles of activity.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003ePA had an overall protective effect on CRC (OR [active vs. inactive]\u0026thinsp;=\u0026thinsp;0.85; 95%CI\u0026thinsp;=\u0026thinsp;0.81\u0026ndash;0.90). The two-step GxE method identified an interaction between rs4779584, an intergenic variant near the \u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e genes, and PA for CRC risk (p-interaction\u0026thinsp;=\u0026thinsp;2.6\u0026times;10\u003csup\u003e\u0026minus;\u0026thinsp;8\u003c/sup\u003e). Stratification by genotype at this locus showed a significant reduction in CRC risk by 20% in active vs. inactive participants with the CC genotype (OR\u0026thinsp;=\u0026thinsp;0.80; 95%CI\u0026thinsp;=\u0026thinsp;0.75\u0026ndash;0.85), but no significant PA\u0026ndash;CRC association among CT or TT carriers. When PA was modeled as quartiles, the 1-d.f. GxE test identified that rs56906466, an intergenic variant near the \u003cem\u003eKCNG1\u003c/em\u003e gene, modified the association between PA and CRC (p-interaction\u0026thinsp;=\u0026thinsp;3.5\u0026times;10\u003csup\u003e\u0026minus;\u0026thinsp;8\u003c/sup\u003e). Stratification at this locus showed that increase in PA (highest vs. lowest quartile) was associated with a lower CRC risk solely among TT carriers (OR\u0026thinsp;=\u0026thinsp;0.77; 95%CI\u0026thinsp;=\u0026thinsp;0.72\u0026ndash;0.82).\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eIn summary, we identified two genetic variants that modified the association between PA and CRC risk. One of them, related to \u003cem\u003eGREM1\u003c/em\u003e and \u003cem\u003eSCG5\u003c/em\u003e, suggests that the bone morphogenetic protein (BMP)-related, inflammatory, and/or insulin signaling pathways may be associated with the protective influence of PA on colorectal carcinogenesis.\u003c/p\u003e","manuscriptTitle":"Genetic risk factors modulate the association between physical activity and colorectal cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-02 06:43:14","doi":"10.21203/rs.3.rs-7350654/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-11-12T10:37:52+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-11-12T07:06:05+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"118817421373976330346498292131721221138","date":"2025-11-10T12:24:48+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-29T05:14:27+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"94542871562192419778803822399507340525","date":"2025-10-19T08:28:11+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-08-22T09:58:59+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-08-12T06:07:16+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-08-12T06:05:12+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Medicine","date":"2025-08-12T02:46:26+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bmed","sideBox":"Learn more about [BMC Medicine](http://bmcmedicine.biomedcentral.com/)","snPcode":"12916","submissionUrl":"https://submission.nature.com/new-submission/12916/3","title":"BMC Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5d6b068c-fc0b-493b-bad5-393defb29dee","owner":[],"postedDate":"September 2nd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-02-09T16:11:27+00:00","versionOfRecord":{"articleIdentity":"rs-7350654","link":"https://doi.org/10.1186/s12916-026-04675-5","journal":{"identity":"bmc-medicine","isVorOnly":false,"title":"BMC Medicine"},"publishedOn":"2026-02-05 15:59:00","publishedOnDateReadable":"February 5th, 2026"},"versionCreatedAt":"2025-09-02 06:43:14","video":"","vorDoi":"10.1186/s12916-026-04675-5","vorDoiUrl":"https://doi.org/10.1186/s12916-026-04675-5","workflowStages":[]},"version":"v1","identity":"rs-7350654","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7350654","identity":"rs-7350654","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}